WOS: 000450140200001 ; A search is performed for a heavy particle decaying into different-flavor, dilepton pairs (e mu, e tau or mu tau), using 36.1 fb(-1) of proton-proton collision data at root s = 13 TeV collected in 2015-2016 by the ATLAS detector at the Large Hadron Collider. No excesses over the Standard Model predictions are observed. Bayesian lower limits at the 95% credibility level are placed on the mass of a Z' boson, the mass of a supersymmetric tau-sneutrino, and on the threshold mass for quantum black-hole production. For the Z' and sneutrino models, upper cross-section limits are converted to upper limits on couplings, which are compared with similar limits from low-energy experiments and which are more stringent for the e tau and mu tau modes. ; ANPCyT, ArgentinaANPCyT; YerPhI, Armenia; ARC, AustraliaAustralian Research Council; BMWFW, Austria; FWF, AustriaAustrian Science Fund (FWF); ANAS, AzerbaijanAzerbaijan National Academy of Sciences (ANAS); SSTC, Belarus; CNPq, BrazilNational Council for Scientific and Technological Development (CNPq); FAPESP, BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); NSERC, CanadaNatural Sciences and Engineering Research Council of Canada; NRC, Canada; CFI, CanadaCanada Foundation for Innovation; CERN; CONICYT, ChileComision Nacional de Investigacion Cientifica y Tecnologica (CONICYT); CAS, ChinaChinese Academy of Sciences; MOST, ChinaMinistry of Science and Technology, China; NSFC, ChinaNational Natural Science Foundation of China; COLCIENCIAS, ColombiaDepartamento Administrativo de Ciencia, Tecnologia e Innovacion Colciencias; MSMT CR, Czech RepublicMinistry of Education, Youth & Sports - Czech RepublicCzech Republic Government; MPO CR, Czech RepublicCzech Republic Government; VSC CR, Czech RepublicCzech Republic Government; DNRF, Denmark; DNSRC, DenmarkDanish Natural Science Research Council; IN2P3-CNRS, FranceCentre National de la Recherche Scientifique (CNRS); CEA-DRF/IRFU, France; SRNSFG, Georgia; BMBF, GermanyFederal Ministry of Education & Research (BMBF); HGF, Germany; MPG, GermanyMax Planck Society; GSRT, GreeceGreek Ministry of Development-GSRT; RGC, Hong Kong SAR, ChinaHong Kong Research Grants Council; ISF, IsraelIsrael Science Foundation; Benoziyo Center, Israel; INFN, ItalyIstituto Nazionale di Fisica Nucleare; MEXT, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); JSPS, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; CNRST, Morocco; NWO, NetherlandsNetherlands Organization for Scientific Research (NWO)Netherlands Government; RCN, Norway; MNiSW, PolandMinistry of Science and Higher Education, Poland; NCN, Poland; FCT, PortugalPortuguese Foundation for Science and Technology; MNE/IFA, Romania; MES of Russia, Russian FederationRussian Federation; NRC KI, Russian Federation; JINR; MESTD, Serbia; MSSR, Slovakia; ARRS, SloveniaSlovenian Research Agency - Slovenia; MIZS, Slovenia; DST/NRF, South Africa; MINECO, Spain; SRC, Sweden; Wallenberg Foundation, Sweden; SERI, Switzerland; Canton of Bern, Switzerland; Canton of Geneva, Switzerland; MOST, TaiwanMinistry of Science and Technology, Taiwan; TAEK, TurkeyMinistry of Energy & Natural Resources - Turkey; STFC, United KingdomScience & Technology Facilities Council (STFC); DOE, United States of AmericaUnited States Department of Energy (DOE); NSF, United States of AmericaNational Science Foundation (NSF); BCKDF, Canada; Canada Council, Canada; CANARIE, Canada; CRC, Canada; Compute Canada, Canada; FQRNT, CanadaFQRNT; Ontario Innovation Trust, Canada; EPLANET, European UnionEuropean Union (EU); ERC, European UnionEuropean Union (EU)European Research Council (ERC); ERDF, European UnionEuropean Union (EU); FP7, European UnionEuropean Union (EU); Horizon 2020, European Union; Marie Sklodowska-Curie Actions, European UnionEuropean Union (EU); Investissement d'Avenir Labex, FranceFrench National Research Agency (ANR); Investissement d'Avenir Idex, FranceFrench National Research Agency (ANR); ANR, FranceFrench National Research Agency (ANR); Region Auvergne, FranceRegion Auvergne-Rhone-Alpes; Fondation Partager le Savoir, France; DFG, GermanyGerman Research Foundation (DFG); AvH Foundation, GermanyAlexander von Humboldt Foundation; Herakleitos programme - EU-ESF; Thales programme - EU-ESF; Aristeia programme - EU-ESF; Greek NSRFGreek Ministry of Development-GSRT; BSF, IsraelUS-Israel Binational Science Foundation; GIF, IsraelGerman-Israeli Foundation for Scientific Research and Development; Minerva, Israel; BRF, Norway; CERCA Programme Generalitat de Catalunya, Spain; Generalitat Valenciana, SpainGeneralitat Valenciana; Royal Society, United KingdomRoyal Society of London; Leverhulme Trust, United KingdomLeverhulme Trust ; We thank CERN for the very successful operation of the LHC, as well as the support staff from our institutions without whom ATLAS could not be operated efficiently. We acknowledge the support of ANPCyT, Argentina; YerPhI, Armenia; ARC, Australia; BMWFW and FWF, Austria; ANAS, Azerbaijan; SSTC, Belarus; CNPq and FAPESP, Brazil; NSERC, NRC and CFI, Canada; CERN; CONICYT, Chile; CAS, MOST and NSFC, China; COLCIENCIAS, Colombia; MSMT CR, MPO CR and VSC CR, Czech Republic; DNRF and DNSRC, Denmark; IN2P3-CNRS, CEA-DRF/IRFU, France; SRNSFG, Georgia; BMBF, HGF, and MPG, Germany; GSRT, Greece; RGC, Hong Kong SAR, China; ISF and Benoziyo Center, Israel; INFN, Italy; MEXT and JSPS, Japan; CNRST, Morocco; NWO, Netherlands; RCN, Norway; MNiSW and NCN, Poland; FCT, Portugal; MNE/IFA, Romania; MES of Russia and NRC KI, Russian Federation; JINR; MESTD, Serbia; MSSR, Slovakia; ARRS and MIZS, Slovenia; DST/NRF, South Africa; MINECO, Spain; SRC and Wallenberg Foundation, Sweden; SERI, SNSF and Cantons of Bern and Geneva, Switzerland; MOST, Taiwan; TAEK, Turkey; STFC, United Kingdom; DOE and NSF, United States of America. In addition, individual groups and members have received support from BCKDF, the Canada Council, CANARIE, CRC, Compute Canada, FQRNT, and the Ontario Innovation Trust, Canada; EPLANET, ERC, ERDF, FP7, Horizon 2020 and Marie Sklodowska-Curie Actions, European Union; Investissements d'Avenir Labex and Idex, ANR, Region Auvergne and Fondation Partager le Savoir, France; DFG and AvH Foundation, Germany; Herakleitos, Thales and Aristeia programmes co-financed by EU-ESF and the Greek NSRF; BSF, GIF and Minerva, Israel; BRF, Norway; CERCA Programme Generalitat de Catalunya, Generalitat Valenciana, Spain; the Royal Society and Leverhulme Trust, United Kingdom. The crucial computing support from all WLCG partners is acknowledged gratefully, in particular from CERN, the ATLAS Tier-1 facilities at TRIUMF (Canada), NDGF (Denmark, Norway, Sweden), CC-IN2P3 (France), KIT/GridKA (Germany), INFN-CNAF (Italy), NL-T1 (Netherlands), PIC (Spain), ASGC (Taiwan), RAL (UK) and BNL (USA), the Tier-2 facilities worldwide and large non-WLCG resource providers. Major contributors of computing resources are listed in Ref. [81].
WOS: 000435653100044 ; A search for W'-boson production in the W' -> t (b) over bar -> q (q) over bar 'b (b) over bar decay channel is presented using 36.1 fb(-1) of 13 TeV proton-proton collision data collected by the ATLAS detector at the Large Hadron Collider in 2015 and 2016. The search is interpreted in terms of both a left-handed and a right-handed chiral W' boson within the mass range 1-5 TeV. Identification of the hadronically decaying top quark is performed using jet substructure tagging techniques based on a shower deconstruction algorithm. No significant deviation from the Standard Model prediction is observed and the results are expressed as upper limits on the W' -> t (b) over bar production cross-section times branching ratio as a function of the W'-boson mass. These limits exclude W' bosons with right-handed couplings with masses below 3.0 TeV and W' bosons with left-handed couplings with masses below 2.9 TeV, at the 95% confidence level. (C) 2018 The Author. Published by Elsevier B.V. ; ANPCyT, ArgentinaANPCyT; YerPhI, Armenia; ARC, AustraliaAustralian Research Council; BMWFW, Austria; FWF, AustriaAustrian Science Fund (FWF); ANAS, AzerbaijanAzerbaijan National Academy of Sciences (ANAS); SSTC, Belarus; CNPq, BrazilNational Council for Scientific and Technological Development (CNPq); FAPESP, BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); NSERC, CanadaNatural Sciences and Engineering Research Council of Canada; NRC, Canada; CFI, CanadaCanada Foundation for Innovation; CERN; CONICYT, ChileComision Nacional de Investigacion Cientifica y Tecnologica (CONICYT); CAS, ChinaChinese Academy of Sciences; MOST, ChinaMinistry of Science and Technology, China; NSFC, ChinaNational Natural Science Foundation of China; COLCIENCIAS, ColombiaDepartamento Administrativo de Ciencia, Tecnologia e Innovacion Colciencias; MSMT CR, Czech RepublicMinistry of Education, Youth & Sports - Czech RepublicCzech Republic Government; MPO CR, Czech RepublicCzech Republic Government; VSC CR, Czech RepublicCzech Republic Government; DNRF, Denmark; DNSRC, DenmarkDanish Natural Science Research Council; IN2P3-CNRS, FranceCentre National de la Recherche Scientifique (CNRS); CEA-DRF/IRFU, France; SRNSFG, Georgia; BMBF, GermanyFederal Ministry of Education & Research (BMBF); HGF, Germany; MPG, GermanyMax Planck Society; GSRT, GreeceGreek Ministry of Development-GSRT; RGC, China; Hong Kong SAR, China; ISF, IsraelIsrael Science Foundation; I-CORE, Israel; INFN, ItalyIstituto Nazionale di Fisica Nucleare; MEXT, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); JSPS, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; CNRST, Morocco; NWO, NetherlandsNetherlands Organization for Scientific Research (NWO)Netherlands Government; RCN, Norway; MNiSW, PolandMinistry of Science and Higher Education, Poland; NCN, Poland; FCT, PortugalPortuguese Foundation for Science and Technology; MNE/IFA, Romania; MES of Russia, Russian FederationRussian Federation; NRC KI, Russian Federation; JINR; MESTD, Serbia; MSSR, Slovakia; ARRS, SloveniaSlovenian Research Agency - Slovenia; MIA, Slovenia; DST/NRF, South Africa; MINECO, Spain; SRC, Sweden; Wallenberg Foundation, Sweden; SERI, Switzerland; SNSF, SwitzerlandSwiss National Science Foundation (SNSF); Canton of Bern, Switzerland; Canton of Geneva, Switzerland; MOST, TaiwanMinistry of Science and Technology, Taiwan; TAEK, TurkeyMinistry of Energy & Natural Resources - Turkey; STFC, United KingdomScience & Technology Facilities Council (STFC); DOE, United States of AmericaUnited States Department of Energy (DOE); NSF, United States of AmericaNational Science Foundation (NSF); BCKDF; Canada Council, Canada; Ontario Innovation Trust, Canada; EPLANET, European UnionEuropean Union (EU); ERC, European UnionEuropean Union (EU)European Research Council (ERC); ERDF, European UnionEuropean Union (EU); FP7, European UnionEuropean Union (EU); Investissements d'Avenir Labex and Idex, FranceFrench National Research Agency (ANR); DFG, GermanyGerman Research Foundation (DFG); AvH Foundation, GermanyAlexander von Humboldt Foundation; Herakleitos programme; EU-ESFEuropean Union (EU); Greek NSRFGreek Ministry of Development-GSRT; BSF, IsraelUS-Israel Binational Science Foundation; GIF, IsraelGerman-Israeli Foundation for Scientific Research and Development; Minerva, Israel; BRF, Norway; CERCA Programme Generalitat de Catalunya, Spain; Royal Society, United KingdomRoyal Society of London; Benoziyo Center, Israel; Canarie, Canada; CRC, Canada; Compute Canada, Canada; FQRNT, CanadaFQRNT; Horizon 2020, European Union; Marie Sklodowska-Curie Actions, European UnionEuropean Union (EU); ANR, FranceFrench National Research Agency (ANR); Region Auvergne, FranceRegion Auvergne-Rhone-Alpes; Fondation Partager le Savoir, France; Thales programme; Aristeia programme; Generalitat Valenciana, SpainGeneralitat Valenciana; Leverhulme Trust, United KingdomLeverhulme Trust ; We acknowledge the support of ANPCyT, Argentina; YerPhI, Armenia; ARC, Australia; BMWFW and FWF, Austria; ANAS, Azerbaijan; SSTC, Belarus; CNPq and FAPESP, Brazil; NSERC, NRC and CFI, Canada; CERN; CONICYT, Chile; CAS, MOST and NSFC, China; COLCIENCIAS, Colombia; MSMT CR, MPO CR and VSC CR, Czech Republic; DNRF and DNSRC, Denmark; IN2P3-CNRS, CEA-DRF/IRFU, France; SRNSFG, Georgia; BMBF, HGF, and MPG, Germany; GSRT, Greece; RGC, Hong Kong SAR, China; ISF, I-CORE and Benoziyo Center, Israel; INFN, Italy; MEXT and JSPS, Japan; CNRST, Morocco; NWO, Netherlands; RCN, Norway; MNiSW and NCN, Poland; FCT, Portugal; MNE/IFA, Romania; MES of Russia and NRC KI, Russian Federation; JINR; MESTD, Serbia; MSSR, Slovakia; ARRS and MIA, Slovenia; DST/NRF, South Africa; MINECO, Spain; SRC and Wallenberg Foundation, Sweden; SERI, SNSF and Cantons of Bern and Geneva, Switzerland; MOST, Taiwan; TAEK, Turkey; STFC, United Kingdom; DOE and NSF, United States of America. In addition, individual groups and members have received support from BCKDF, the Canada Council, Canarie, CRC, Compute Canada, FQRNT, and the Ontario Innovation Trust, Canada; EPLANET, ERC, ERDF, FP7, Horizon 2020 and Marie Sklodowska-Curie Actions, European Union; Investissements d'Avenir Labex and Idex, ANR, Region Auvergne and Fondation Partager le Savoir, France; DFG and AvH Foundation, Germany; Herakleitos, Thales and Aristeia programmes co-financed by EU-ESF and the Greek NSRF; BSF, GIF and Minerva, Israel; BRF, Norway; CERCA Programme Generalitat de Catalunya, Generalitat Valenciana, Spain; the Royal Society and Leverhulme Trust, United Kingdom.r The crucial computing support from all WLCG partners is acknowledged gratefully, in particular from CERN, the ATLAS Tier 1 facilities at TRIUMF (Canada), NDGF (Denmark, Norway, Sweden), CC-IN2P3 (France), KIT/GridKA (Germany), INFN-CNAF (Italy), NL-T1 (Netherlands), PIC (Spain), ASGC (Taiwan), RAL (UK) and BNL (USA), the Tier -2 facilities worldwide and large non-WLCG resource providers. Major contributors of computing resources are listed in Ref. [78].
WOS: 000429098900004 ; A search for heavy resonances decaying into a Higgs boson (H) and a new particle (X) is reported, utilizing 36.1 fb(-1) of proton-proton collision data at root s = 13 TeV collected during 2015 and 2016 with the ATLAS detector at the CERN Large Hadron Collider. The particle Xis assumed to decay to a pair of light quarks, and the fully hadronic final state XH -> q (q) over bar 'b (b) over bar is analysed. The search considers the regime of high XH resonance masses, where the X and H bosons are both highly Lorentz-boosted and are each reconstructed using a single jet with large radius parameter. A two-dimensional phase space of XH mass versus X mass is scanned for evidence of a signal, over a range of XH resonance mass values between 1 TeV and 4 TeV, and for X particles with masses from 50 GeV to 1000 GeV. All search results are consistent with the expectations for the background due to Standard Model processes, and 95% CL upper limits are set, as a function of XH and X masses, on the production cross-section of the XH -> q (q) over bar 'b (b) over bar resonance. (c) 2018 The Author(s). Published by Elsevier B.V. ; ANPCyT, ArgentinaANPCyT; YerPhI, Armenia; ARC, AustraliaAustralian Research Council; BMWFW, Austria; FWF, AustriaAustrian Science Fund (FWF); ANAS, AzerbaijanAzerbaijan National Academy of Sciences (ANAS); SSTC, Belarus; CNPq, BrazilNational Council for Scientific and Technological Development (CNPq); FAPESP, BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); NSERC, CanadaNatural Sciences and Engineering Research Council of Canada; NRC, Canada; CFI, CanadaCanada Foundation for Innovation; CERN; CONICYT, ChileComision Nacional de Investigacion Cientifica y Tecnologica (CONICYT); CAS, ChinaChinese Academy of Sciences; MOST, ChinaMinistry of Science and Technology, China; NSFC, ChinaNational Natural Science Foundation of China; COLCIENCIAS, ColombiaDepartamento Administrativo de Ciencia, Tecnologia e Innovacion Colciencias; MSMT CR, Czech RepublicMinistry of Education, Youth & Sports - Czech RepublicCzech Republic Government; MPO CR, Czech RepublicCzech Republic Government; VSC CR, Czech RepublicCzech Republic Government; DNRF, Denmark; DNSRC, DenmarkDanish Natural Science Research Council; IN2P3-CNRS, FranceCentre National de la Recherche Scientifique (CNRS); CEA-DRF/IRFU, France; SRNSF, Georgia; BMBF, GermanyFederal Ministry of Education & Research (BMBF); HGF, Germany; MPG, GermanyMax Planck Society; GSRT, GreeceGreek Ministry of Development-GSRT; RGC, Hong Kong SAR, ChinaHong Kong Research Grants Council; ISF, IsraelIsrael Science Foundation; I-CORE, Israel; Benoziyo Center, Israel; INFN, ItalyIstituto Nazionale di Fisica Nucleare; MEXT, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); JSPS, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; CNRST, Morocco; NWO, NetherlandsNetherlands Organization for Scientific Research (NWO)Netherlands Government; RCN, Norway; MNiSW, PolandMinistry of Science and Higher Education, Poland; NCN, Poland; FCT, PortugalPortuguese Foundation for Science and Technology; MNE/IFA, Romania; MES of Russia, Russian FederationRussian Federation; NRC KI, Russian Federation; JINR; MESTD, Serbia; MSSR, Slovakia; ARRS, SloveniaSlovenian Research Agency - Slovenia; MIZS, Slovenia; DST/NRF, South Africa; MINECO, Spain; SRC, Sweden; Wallenberg Foundation, Sweden; SERI, Switzerland; SNSF, SwitzerlandSwiss National Science Foundation (SNSF); Canton of Bern, Switzerland; Canton of Geneva, Switzerland; MOST, TaiwanMinistry of Science and Technology, Taiwan; TAEK, TurkeyMinistry of Energy & Natural Resources - Turkey; STFC, United KingdomScience & Technology Facilities Council (STFC); DOE, United States of AmericaUnited States Department of Energy (DOE); NSF, United States of AmericaNational Science Foundation (NSF); BCKDF, Canada; Canada Council, Canada; CANARIE, Canada; CRC, Canada; Compute Canada, Canada; FQRNT, CanadaFQRNT; Ontario Innovation Trust, Canada; EPLANET, France; ERC, France; ERDF, France; FP7, France; Horizon 2020, France; Marie Sklodowska-Curie Actions, France; European Union, FranceEuropean Union (EU); Investissements d'Avenir Labex, FranceFrench National Research Agency (ANR); Idex, France; ANR, FranceFrench National Research Agency (ANR); Region Auvergne, FranceRegion Auvergne-Rhone-Alpes; Fondation Partager le Savoir, France; DFG, GermanyGerman Research Foundation (DFG); AvH Foundation, GermanyAlexander von Humboldt Foundation; Herakleitos; Thales; Aristeia programmes - EU-ESF; Greek NSRFGreek Ministry of Development-GSRT; BSF, IsraelUS-Israel Binational Science Foundation; GIF, IsraelGerman-Israeli Foundation for Scientific Research and Development; Minerva, Israel; BRF, Norway; CERCA Programme Generalitat de Catalunya, Spain; Generalitat Valenciana, SpainGeneralitat Valenciana; Royal Society, United KingdomRoyal Society of London; Leverhulme Trust, United KingdomLeverhulme Trust ; We acknowledge the support of ANPCyT, Argentina; YerPhI, Armenia; ARC, Australia; BMWFW and FWF, Austria; ANAS, Azerbaijan; SSTC, Belarus; CNPq and FAPESP, Brazil; NSERC, NRC and CFI, Canada; CERN; CONICYT, Chile; CAS, MOST and NSFC, China; COLCIENCIAS, Colombia; MSMT CR, MPO CR and VSC CR, Czech Republic; DNRF and DNSRC, Denmark; IN2P3-CNRS, CEA-DRF/IRFU, France; SRNSF, Georgia; BMBF, HGF, and MPG, Germany; GSRT, Greece; RGC, Hong Kong SAR, China; ISF, I-CORE and Benoziyo Center, Israel; INFN, Italy; MEXT and JSPS, Japan; CNRST, Morocco; NWO, Netherlands; RCN, Norway; MNiSW and NCN, Poland; FCT, Portugal; MNE/IFA, Romania; MES of Russia and NRC KI, Russian Federation; JINR; MESTD, Serbia; MSSR, Slovakia; ARRS and MIZS, Slovenia; DST/ NRF, South Africa; MINECO, Spain; SRC and Wallenberg Foundation, Sweden; SERI, SNSF and Cantons of Bern and Geneva, Switzerland; MOST, Taiwan; TAEK, Turkey; STFC, United Kingdom; DOE and NSF, United States of America. In addition, individual groups and members have received support from BCKDF, the Canada Council, CANARIE, CRC, Compute Canada, FQRNT, and the Ontario Innovation Trust, Canada; EPLANET, ERC, ERDF, FP7, Horizon 2020 and Marie Sklodowska-Curie Actions, European Union; Investissements d'Avenir Labex and Idex, ANR, Region Auvergne and Fondation Partager le Savoir, France; DFG and AvH Foundation, Germany; Herakleitos, Thales and Aristeia programmes co-financed by EU-ESF and the Greek NSRF; BSF, GIF and Minerva, Israel; BRF, Norway; CERCA Programme Generalitat de Catalunya, Generalitat Valenciana, Spain; the Royal Society and Leverhulme Trust, United Kingdom.
WOS: 000427620000001 ; PubMed: 31265007 ; A search for doubly charged Higgs bosons with pairs of prompt, isolated, highly energetic leptons with the same electric charge is presented. The search uses a proton-proton collision data sample at a centre-of-mass energy of 13 TeV corresponding to 36.1 fb(-1) of integrated luminosity recorded in 2015 and 2016 by the ATLAS detector at the LHC. This analysis focuses on the decays H-+/-+/- -> e(+/-)e(+/-), H-+/-+/- -> e(+/-)mu(+/-) and H-+/-+/- -> mu(+/-)mu(+/-), fitting the dilepton mass spectra in several exclusive signal regions. No significant evidence of a signal is observed and corresponding limits on the production cross-section and consequently a lower limit on m(H-+/-+/-) are derived at 95% confidence level. With l(+/-)l(+/-) = e(+/-)e(+/-)/mu(+/-)mu(+/-)/e(+/-)mu(+/-), the observed lower limit on the mass of a doubly charged Higgs boson only coupling to left-handed leptons varies from 770 to 870GeV (850GeV expected) for B(H-+/-+/- -> l(+/-)l(+/-)) = 100% and both the expected and observed mass limits are above 450GeV for B(H-+/-+/- -> l(+/-)l(+/-)) = 10% and any combination of partial branching ratios. ; ANPCyT, ArgentinaANPCyT; YerPhI, Armenia; ARC, AustraliaAustralian Research Council; BMWFW, Austria; FWF, AustriaAustrian Science Fund (FWF); ANAS, AzerbaijanAzerbaijan National Academy of Sciences (ANAS); SSTC, Belarus; CNPq, BrazilNational Council for Scientific and Technological Development (CNPq); FAPESP, BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); NSERC, CanadaNatural Sciences and Engineering Research Council of Canada; NRC, Canada; CFI, CanadaCanada Foundation for Innovation; CERN, Chile; CONICYT, ChileComision Nacional de Investigacion Cientifica y Tecnologica (CONICYT); CAS, ChinaChinese Academy of Sciences; MOST, ChinaMinistry of Science and Technology, China; NSFC, ChinaNational Natural Science Foundation of China; COLCIENCIAS, ColombiaDepartamento Administrativo de Ciencia, Tecnologia e Innovacion Colciencias; MSMT CR, Czech RepublicMinistry of Education, Youth & Sports - Czech RepublicCzech Republic Government; MPO CR, Czech RepublicCzech Republic Government; VSC CR, Czech RepublicCzech Republic Government; DNRF, Denmark; DNSRC, DenmarkDanish Natural Science Research Council; IN2P3-CNRS, FranceCentre National de la Recherche Scientifique (CNRS); CEA-DRF/IRFU, France; SRNSFG, Georgia; BMBF, GermanyFederal Ministry of Education & Research (BMBF); HGF, Germany; MPG, GermanyMax Planck Society; GSRT, GreeceGreek Ministry of Development-GSRT; RGC, China; Hong Kong SAR, China; ISF, IsraelIsrael Science Foundation; I-CORE, Israel; Benoziyo Center, Israel; INFN, ItalyIstituto Nazionale di Fisica Nucleare; MEXT, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); JSPS, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; CNRST, Morocco; NWO, The NetherlandsNetherlands Organization for Scientific Research (NWO)Netherlands Government; RCN, Norway; MNiSW, PolandMinistry of Science and Higher Education, Poland; NCN, Poland; FCT, PortugalPortuguese Foundation for Science and Technology; MNE/IFA, Romania; MES of Russia, Russian FederationRussian Federation; NRC KI, Russian Federation; JINR, Serbia; MESTD, Serbia; MSSR, Slovakia; ARRS, SloveniaSlovenian Research Agency - Slovenia; MIZS, Slovenia; DST/NRF, South Africa; MINECO, Spain; SRC, Sweden; Wallenberg Foundation, Sweden; SERI, Switzerland; SNSF, SwitzerlandSwiss National Science Foundation (SNSF); Canton of Bern, Switzerland; MOST, TaiwanMinistry of Science and Technology, Taiwan; TAEK, TurkeyMinistry of Energy & Natural Resources - Turkey; STFC, UKScience & Technology Facilities Council (STFC); DOE, USAUnited States Department of Energy (DOE); NSF, USANational Science Foundation (NSF); BCKDF, Canada; Canada Council, Canada; CANARIE, Canada; CRC, Canada; Compute Canada; FQRNT, CanadaFQRNT; Ontario Innovation Trust, Canada; EPLANET; ERCEuropean Research Council (ERC); ERDFEuropean Union (EU); FP7, Horizon 2020 and Marie Sklodowska-Curie Actions; European UnionEuropean Union (EU); Investissements d'Avenir Labex and Idex, FranceFrench National Research Agency (ANR); ANR, FranceFrench National Research Agency (ANR); Region Auvergne, FranceRegion Auvergne-Rhone-Alpes; Fondation Partager le Savoir, France; DFG, GermanyGerman Research Foundation (DFG); AvH Foundation, GermanyAlexander von Humboldt Foundation; Herakleitos, Thales and Aristeia programmes by EU-ESF; Greek NSRFGreek Ministry of Development-GSRT; BSF, IsraelUS-Israel Binational Science Foundation; GIF, IsraelGerman-Israeli Foundation for Scientific Research and Development; Minerva, Israel; BRF, Norway; CERCA Programme Generalitat de Catalunya, Spain; Generalitat Valenciana, SpainGeneralitat Valenciana; Royal Society, United KingdomRoyal Society of London; Leverhulme Trust, United KingdomLeverhulme Trust; Canton of Geneva, Switzerland ; We thank CERN for the very successful operation of the LHC, as well as the support staff from our institutions without whom ATLAS could not be operated efficiently. We acknowledge the support of ANPCyT, Argentina; YerPhI, Armenia; ARC, Australia; BMWFW and FWF, Austria; ANAS, Azerbaijan; SSTC, Belarus; CNPq and FAPESP, Brazil; NSERC, NRC and CFI, Canada; CERN; CONICYT, Chile; CAS, MOST and NSFC, China; COLCIENCIAS, Colombia; MSMT CR, MPO CR and VSC CR, Czech Republic; DNRF and DNSRC, Denmark; IN2P3-CNRS, CEA-DRF/IRFU, France; SRNSFG, Georgia; BMBF, HGF, and MPG, Germany; GSRT, Greece; RGC, Hong Kong SAR, China; ISF, I-CORE and Benoziyo Center, Israel; INFN, Italy; MEXT and JSPS, Japan; CNRST, Morocco; NWO, The Netherlands; RCN, Norway; MNiSW and NCN, Poland; FCT, Portugal; MNE/IFA, Romania; MES of Russia and NRC KI, Russian Federation; JINR; MESTD, Serbia; MSSR, Slovakia; ARRS and MIZS, Slovenia; DST/NRF, South Africa; MINECO, Spain; SRC and Wallenberg Foundation, Sweden; SERI, SNSF and Cantons of Bern and Geneva, Switzerland; MOST, Taiwan; TAEK, Turkey; STFC, UK; DOE and NSF, USA. In addition, individual groups and members have received support from BCKDF, the Canada Council, CANARIE, CRC, Compute Canada, FQRNT, and the Ontario Innovation Trust, Canada; EPLANET, ERC, ERDF, FP7, Horizon 2020 and Marie Sklodowska-Curie Actions, European Union; Investissements d'Avenir Labex and Idex, ANR, Region Auvergne and Fondation Partager le Savoir, France; DFG and AvH Foundation, Germany; Herakleitos, Thales and Aristeia programmes co-financed by EU-ESF and the Greek NSRF; BSF, GIF and Minerva, Israel; BRF, Norway; CERCA Programme Generalitat de Catalunya, Generalitat Valenciana, Spain; the Royal Society and Leverhulme Trust, United Kingdom. The crucial computing support from all WLCG partners is acknowledged gratefully, in particular from CERN, theATLAS Tier-1 facilities at TRIUMF (Canada), NDGF (Denmark, Norway, Sweden), CC-IN2P3 (France), KIT/GridKA (Germany), INFN-CNAF (Italy), NL-T1 (The Netherlands), PIC (Spain), ASGC (Taiwan), RAL (UK) and BNL (USA), the Tier-2 facilities worldwide and large non-WLCG resource providers. Major contributors of computing resources are listed in Ref. [86].
WOS: 000446948800005 ; A measurement of the fragmentation functions of jets into charged particles in p Pb collisions and pp collisions is presented. The analysis utilizes 28 nb(-1) of p Pb data and 26 pb(-1) of pp data, both at root(TN)-T-s= 5.02 TeV, collected in 2013 and 2015, respectively, with the ATLAS detector at the LHC. The measurement is reported in the centre-of-mass frame of the nucleon-nucleon system for jets in the rapidity range vertical bar y*vertical bar <1.6 and with transverse momentum 45 < p(T) < 260 GeV. Results are presented both as a function of the charged-particle transverse momentum and as a function of the longitudinal momentum fraction of the particle with respect to the jet. The pp fragmentation functions are compared with results from Monte Carlo event generators and two theoretical models. The ratios of the p +Pb to pp fragmentation functions are found to be consistent with unity. (C) 2018 CERN for the benefit of the ATLAS Collaboration. Published by Elsevier B.V. ; ANPCyT, ArgentinaANPCyT; YerPhI, Armenia; ARC, AustraliaAustralian Research Council; BMWFW, Austria; FWF, AustriaAustrian Science Fund (FWF); ANAS, AzerbaijanAzerbaijan National Academy of Sciences (ANAS); SSTC, Belarus; CNPq, BrazilNational Council for Scientific and Technological Development (CNPq); FAPESP, BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); NSERC, CanadaNatural Sciences and Engineering Research Council of Canada; NRC, Canada; CFI, CanadaCanada Foundation for Innovation; CERN; CONICYT, ChileComision Nacional de Investigacion Cientifica y Tecnologica (CONICYT); CAS, ChinaChinese Academy of Sciences; MOST, ChinaMinistry of Science and Technology, China; NSFC, ChinaNational Natural Science Foundation of China; COLCIENCIAS, ColombiaDepartamento Administrativo de Ciencia, Tecnologia e Innovacion Colciencias; MSMT CR, Czech RepublicMinistry of Education, Youth & Sports - Czech RepublicCzech Republic Government; MPO CR, Czech RepublicCzech Republic Government; VSC CR, Czech RepublicCzech Republic Government; DNRF, Denmark; DNSRC, DenmarkDanish Natural Science Research Council; IN2P3-CNRS, FranceCentre National de la Recherche Scientifique (CNRS); CEA-DRF/IRFU, France; SRNSFG, Georgia; BMBF, GermanyFederal Ministry of Education & Research (BMBF); HGF, Germany; MPG, GermanyMax Planck Society; GSRT, GreeceGreek Ministry of Development-GSRT; RGC, Hong Kong SAR, ChinaHong Kong Research Grants Council; ISF, IsraelIsrael Science Foundation; I-CORE, Israel; Benoziyo Center, Israel; INFN, ItalyIstituto Nazionale di Fisica Nucleare; MEXT, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); JSPS, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; CNRST, Morocco; NWO, NetherlandsNetherlands Organization for Scientific Research (NWO)Netherlands Government; RCN, Norway; MNiSW, PolandMinistry of Science and Higher Education, Poland; NCN, Poland; FCT, PortugalPortuguese Foundation for Science and Technology; MNE/IFA, Romania; MES of Russia, Russian FederationRussian Federation; NRC KI, Russian Federation; JINR; MESTD, Serbia; MSSR, Slovakia; ARRS, SloveniaSlovenian Research Agency - Slovenia; MIZS, Slovenia; DST/NRF, South Africa; MINECO, Spain; SRC, Sweden; Wallenberg Foundation, Sweden; SERI, Switzerland; SNSF, SwitzerlandSwiss National Science Foundation (SNSF); Canton of Bern, Switzerland; Canton of Geneva, Switzerland; MOST, TaiwanMinistry of Science and Technology, Taiwan; TAEK, TurkeyMinistry of Energy & Natural Resources - Turkey; STFC, United KingdomScience & Technology Facilities Council (STFC); DOE, United States of AmericaUnited States Department of Energy (DOE); NSF, United States of AmericaNational Science Foundation (NSF); BCKDF, Canada; Canada Council, Canada; CANARIE, Canada; CRC, Canada; Compute Canada, Canada; FQRNT, CanadaFQRNT; Ontario Innovation Trust, Canada; EPLANET, European UnionEuropean Union (EU); ERC, European UnionEuropean Union (EU)European Research Council (ERC); ERDF, European UnionEuropean Union (EU); FP7, European UnionEuropean Union (EU); Horizon 2020, European Union; Marie Sklodowska-Curie Actions, European UnionEuropean Union (EU); Investissement d'Avenir Labex, FranceFrench National Research Agency (ANR); Investissement d'Avenir Idex, FranceFrench National Research Agency (ANR); ANR, FranceFrench National Research Agency (ANR); Region Auvergne, FranceRegion Auvergne-Rhone-Alpes; Fondation Partager le Savoir, France; DFG, GermanyGerman Research Foundation (DFG); AvH Foundation, GermanyAlexander von Humboldt Foundation; Herakleitos programme - EU-ESF; Thales programme - EU-ESF; Greek NSRFGreek Ministry of Development-GSRT; BSF, IsraelUS-Israel Binational Science Foundation; GIF, IsraelGerman-Israeli Foundation for Scientific Research and Development; Minerva, Israel; BRF, Norway; CERCA Programme Generalitat de Catalunya, Spain; Generalitat Valenciana, SpainGeneralitat Valenciana; Royal Society, United KingdomRoyal Society of London; Leverhulme Trust, United KingdomLeverhulme Trust ; We acknowledge the support of ANPCyT, Argentina; YerPhI, Armenia; ARC, Australia; BMWFW and FWF, Austria; ANAS, Azerbaijan; SSTC, Belarus; CNPq and FAPESP, Brazil; NSERC, NRC and CFI, Canada; CERN; CONICYT, Chile; CAS, MOST and NSFC, China; COLCIENCIAS, Colombia; MSMT CR, MPO CR and VSC CR, Czech Republic; DNRF and DNSRC, Denmark; IN2P3-CNRS, CEA-DRF/IRFU, France; SRNSFG, Georgia; BMBF, HGF, and MPG, Germany; GSRT, Greece; RGC, Hong Kong SAR, China; ISF, I-CORE and Benoziyo Center, Israel; INFN, Italy; MEXT and JSPS, Japan; CNRST, Morocco; NWO, Netherlands; RCN, Norway; MNiSW and NCN, Poland; FCT, Portugal; MNE/IFA, Romania; MES of Russia and NRC KI, Russian Federation; JINR; MESTD, Serbia; MSSR, Slovakia; ARRS and MIZS, Slovenia; DST/NRF, South Africa; MINECO, Spain; SRC and Wallenberg Foundation, Sweden; SERI, SNSF and Cantons of Bern and Geneva, Switzerland; MOST, Taiwan; TAEK, Turkey; STFC, United Kingdom; DOE and NSF, United States of America. In addition, individual groups and members have received support from BCKDF, the Canada Council, CANARIE, CRC, Compute Canada, FQRNT, and the Ontario Innovation Trust, Canada; EPLANET, ERC, ERDF, FP7, Horizon 2020 and Marie Sklodowska-Curie Actions, European Union; Investissements d'Avenir Labex and Idex, ANR, Region Auvergne and Fondation Partager le Savoir, France; DFG and AvH Foundation, Germany; Herakleitos, Thales and Aristeia programmes co-financed by EU-ESF and the Greek NSRF; BSF, GIF and Minerva, Israel; BRF, Norway; CERCA Programme Generalitat de Catalunya, Generalitat Valenciana, Spain; the Royal Society and Leverhulme Trust, United Kingdom. The crucial computing support from all WLCG partners is acknowledged gratefully, in particular from CERN, the ATLAS Tier-1 facilities at TRIUMF (Canada), NDGF (Denmark, Norway, Sweden), CC-IN2P3 (France), KIT/GridKA (Germany), INFN-CNAF (Italy), NL-T1 (Netherlands), PIC (Spain), ASGC (Taiwan), RAL (UK) and BNL (USA), the Tier-2 facilities worldwide and large non-WLCG resource providers. Major contributors of computing resources are listed in Ref. [54].
WOS: 000432959900001 ; A search for the standard model Higgs boson produced in association with a top-quark pair, t(t)overbarH, is presented. The analysis uses 36.1 fb(-1) of pp collision data at root s = 13 TeV collected with the ATLAS detector at the Large Hadron Collider in 2015 and 2016. The search targets the H -> b(b)overbar decay mode. The selected events contain either one or two electrons or muons from the top-quark decays, and are then categorized according to the number of jets and how likely these are to contain b-hadrons. Multivariate techniques are used to discriminate between signal and background events, the latter being dominated by ft + jets production. For a Higgs boson mass of 125 GeV, the ratio of the measured t(t)overbarH signal cross-section to the standard model expectation is found to be mu = 0.84(-0.61)(+0.64). A value of mu greater than 2.0 is excluded at 95% confidence level (C.L.) while the expected upper limit is mu < 1.2 in the absence of a t(t)overbarH signal. ; ANPCyT, ArgentinaANPCyT; YerPhI, Armenia; ARC, AustraliaAustralian Research Council; BMWFW, Austria; FWF, AustriaAustrian Science Fund (FWF); ANAS, AzerbaijanAzerbaijan National Academy of Sciences (ANAS); SSTC, Belarus; CNPq, BrazilNational Council for Scientific and Technological Development (CNPq); FAPESP, BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); NSERC, CanadaNatural Sciences and Engineering Research Council of Canada; NRC, Canada; CFI, CanadaCanada Foundation for Innovation; CERN; CONICYT, ChileComision Nacional de Investigacion Cientifica y Tecnologica (CONICYT); CAS, ChinaChinese Academy of Sciences; MOST, ChinaMinistry of Science and Technology, China; NSFC, ChinaNational Natural Science Foundation of China; COLCIENCIAS, ColombiaDepartamento Administrativo de Ciencia, Tecnologia e Innovacion Colciencias; MSMT CR, Czech RepublicMinistry of Education, Youth & Sports - Czech RepublicCzech Republic Government; MPO CR, Czech RepublicCzech Republic Government; VSC CR, Czech RepublicCzech Republic Government; DNRF, Denmark; DNSRC, DenmarkDanish Natural Science Research Council; IN2P3-CNRS, FranceCentre National de la Recherche Scientifique (CNRS); CEA-DRF/IRFU, France; SRNSFG, Georgia; BMBF, GermanyFederal Ministry of Education & Research (BMBF); HGF, Germany; MPG, GermanyMax Planck Society; GSRT, GreeceGreek Ministry of Development-GSRT; RGC, Hong Kong SAR, ChinaHong Kong Research Grants Council; ISF, IsraelIsrael Science Foundation; I-CORE, Israel; Benoziyo Center, Israel; INFN, ItalyIstituto Nazionale di Fisica Nucleare; MEXT, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); JSPS, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; CNRST, Morocco; NWO, NetherlandsNetherlands Organization for Scientific Research (NWO)Netherlands Government; RCN, Norway; MNiSW, PolandMinistry of Science and Higher Education, Poland; NCN, Poland; FCT, PortugalPortuguese Foundation for Science and Technology; MNE/IFA, Romania; MES of Russia, Russian FederationRussian Federation; NRC KI, Russian Federation; JINR; MESTD, Serbia; MSSR, Slovakia; ARRS, SloveniaSlovenian Research Agency - Slovenia; MIZS, Slovenia; DST/NRF, South Africa; MINECO, Spain; SRC, Sweden; Wallenberg Foundation, Sweden; SERI, Switzerland; SNSF, SwitzerlandSwiss National Science Foundation (SNSF); Canton of Bern, Switzerland; Canton of Geneva, Switzerland; MOST, TaiwanMinistry of Science and Technology, Taiwan; TAEK, TurkeyMinistry of Energy & Natural Resources - Turkey; STFC, United KingdomScience & Technology Facilities Council (STFC); DOE, USAUnited States Department of Energy (DOE); NSF, USANational Science Foundation (NSF); BCKDF; Canada Council; CANARIE; CRCAustralian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme; Compute Canada; FQRNTFQRNT; Ontario Innovation Trust, Canada; EPLANET; ERCEuropean Research Council (ERC); ERDFEuropean Union (EU); FP7; Horizon; Marie Sklodowska-Curie Actions, European UnionEuropean Union (EU); Investissements d'Avenir Labex and Idex, ANRFrench National Research Agency (ANR); Region AuvergneRegion Auvergne-Rhone-Alpes; Fondation Partager le Savoir, France; DFG, GermanyGerman Research Foundation (DFG); AvH Foundation, GermanyAlexander von Humboldt Foundation; Herakleitos, Thales and Aristeia programmes - EU-ESF; Greek NSRFGreek Ministry of Development-GSRT; BSF, IsraelUS-Israel Binational Science Foundation; GIF, IsraelGerman-Israeli Foundation for Scientific Research and Development; Minerva, Israel; BRF, Norway; CERCA Programme Generalitat de Catalunya; Generalitat Valenciana, SpainGeneralitat Valenciana; Royal Society, United KingdomRoyal Society of London; Leverhulme Trust, United KingdomLeverhulme Trust ; We thank CERN for the very successful operation of the LHC, as well as the support staff from our institutions without whom ATLAS could not be operated efficiently. We acknowledge the support of ANPCyT, Argentina; YerPhI, Armenia; ARC, Australia; BMWFW and FWF, Austria; ANAS, Azerbaijan; SSTC, Belarus; CNPq and FAPESP, Brazil; NSERC, NRC and CFI, Canada; CERN; CONICYT, Chile; CAS, MOST and NSFC, China; COLCIENCIAS, Colombia; MSMT CR, MPO CR and VSC CR, Czech Republic; DNRF and DNSRC, Denmark; IN2P3-CNRS, CEA-DRF/IRFU, France; SRNSFG, Georgia; BMBF, HGF, and MPG, Germany; GSRT, Greece; RGC, Hong Kong SAR, China; ISF, I-CORE and Benoziyo Center, Israel; INFN, Italy; MEXT and JSPS, Japan; CNRST, Morocco; NWO, Netherlands; RCN, Norway; MNiSW and NCN, Poland FCT, Portugal; MNE/IFA, Romania; MES of Russia and NRC KI, Russian Federation; JINR; MESTD, Serbia; MSSR, Slovakia; ARRS and MIZS, Slovenia; DST/NRF, South Africa; MINECO, Spain; SRC and Wallenberg Foundation, Sweden; SERI, SNSF and Cantons of Bern and Geneva, Switzerland; MOST, Taiwan; TAEK, Turkey; STFC, United Kingdom; DOE and NSF, USA. In addition, individual groups and members have received support from BCKDF, the Canada Council, CANARIE, CRC, Compute Canada, FQRNT, and the Ontario Innovation Trust, Canada; EPLANET, ERC, ERDF, FP7, Horizon 2020 and Marie Sklodowska-Curie Actions, European Union; Investissements d'Avenir Labex and Idex, ANR, Region Auvergne and Fondation Partager le Savoir, France; DFG and AvH Foundation, Germany; Herakleitos, Thales and Aristeia programmes co-financed by EU-ESF and the Greek NSRF; BSF, GIF and Minerva, Israel; BRF, Norway; CERCA Programme Generalitat de Catalunya, Generalitat Valenciana, Spain; the Royal Society and Leverhulme Trust, United Kingdom. The crucial computing support from all WLCG partners is acknowledged gratefully, in particular from CERN, the ATLAS Tier-1 facilities at TRIUMF (Canada), NDGF (Denmark, Norway, Sweden), CC-IN2P3 (France), KIT/GridKA (Germany), INFN-CNAF (Italy), NL-T1 (Netherlands), PIC (Spain), ASGC (Taiwan), RAL (UK) and BNL (USA), the Tier-2 facilities worldwide and large non-WLCG resource providers. Major contributors of computing resources are listed in Ref. [100].
WOS: 000417789700001 ; A search for strongly produced supersymmetric particles using signatures involving multiple energetic jets and either two isolated same-sign leptons (e or mu), or at least three isolated leptons, is presented. The analysis relies on the identification of b-jets and high missing transverse momentum to achieve good sensitivity. A data sample of proton-proton collisions at root s = 13 TeV recorded with the ATLAS detector at the Large Hadron Collider in 2015 and 2016, corresponding to a total integrated luminosity of 36.1 fb(-1), is used for the search. No significant excess over the Standard Model prediction is observed. The results are interpreted in several simplified supersymmetric models featuring R-parity conservation or R-parity violation, extending the exclusion limits from previous searches. In models considering gluino pair production, gluino masses are excluded up to 1.87 TeV at 95% confidence level. When bottom squarks are pair-produced and decay to a chargino and a top quark, models with bottom squark masses below 700 GeV and light neutralinos are excluded at 95% confidence level. In addition, model-independent limits are set on a possible contribution of new phenomena to the signal region yields. ; ARRS, SloveniaSlovenian Research Agency - Slovenia; MSSR, Slovakia; ANPCyT, ArgentinaANPCyT; BMWFW, Austria; Fondation Partager le Savoir, France; ARC, AustraliaAustralian Research Council; ANAS, AzerbaijanAzerbaijan National Academy of Sciences (ANAS); DNRF, Denmark; AvH Foundation, GermanyAlexander von Humboldt Foundation; FWF, AustriaAustrian Science Fund (FWF); VSC CR, Czech RepublicCzech Republic Government; DFG, GermanyGerman Research Foundation (DFG); CNPq, BrazilNational Council for Scientific and Technological Development (CNPq); Herakleitos programme - EU-ESF; SSTC, Belarus; NSERC, CanadaNatural Sciences and Engineering Research Council of Canada; FAPESP, BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Thales programme - EU-ESF; MIZS, Slovenia; DST/NRF, South Africa; MSMT CR, Czech RepublicMinistry of Education, Youth & Sports - Czech RepublicCzech Republic Government; Investissements d'Avenir Labex and Idex, FranceFrench National Research Agency (ANR); MINECO, Spain; MPO CR, Czech RepublicCzech Republic Government; Wallenberg Foundation, Sweden; Region Auvergne, FranceRegion Auvergne-Rhone-Alpes; YerPhI, Armenia; SRC, Sweden; ANR, FranceFrench National Research Agency (ANR); GSRT, GreeceGreek Ministry of Development-GSRT; BRF, Norway; CONICYT, ChileComision Nacional de Investigacion Cientifica y Tecnologica (CONICYT); MPG, GermanyMax Planck Society; SERI, Switzerland; Minerva, Israel; MOST, ChinaMinistry of Science and Technology, China; Canton of Bern, Switzerland; Generalitat Valenciana, SpainGeneralitat Valenciana; CAS, ChinaChinese Academy of Sciences; SNSF, SwitzerlandSwiss National Science Foundation (SNSF); CERCA Programme Generalitat de Catalunya, Spain; COLCIENCIAS, ColombiaDepartamento Administrativo de Ciencia, Tecnologia e Innovacion Colciencias; MOST, TaiwanMinistry of Science and Technology, Taiwan; Leverhulme Trust, United KingdomLeverhulme Trust; NSFC, ChinaNational Natural Science Foundation of China; Canton of Geneva, Switzerland; Royal Society, United KingdomRoyal Society of London; STFC, United KingdomScience & Technology Facilities Council (STFC); TAEK, TurkeyMinistry of Energy & Natural Resources - Turkey; DNSRC, DenmarkDanish Natural Science Research Council; IN2P3-CNRS, FranceCentre National de la Recherche Scientifique (CNRS); NRC, Canada; SRNSF, Georgia; Greek NSRFGreek Ministry of Development-GSRT; CEA-DSM/IRFU, France; Aristeia programme - EU-ESF; CERN; HGF, Germany; GIF, IsraelGerman-Israeli Foundation for Scientific Research and Development; CFI, CanadaCanada Foundation for Innovation; BMBF, GermanyFederal Ministry of Education & Research (BMBF); BSF, IsraelUS-Israel Binational Science Foundation; NSF, United States of AmericaNational Science Foundation (NSF); DOE, United States of AmericaUnited States Department of Energy (DOE); CNRST, Morocco; JSPS, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; Ontario Innovation Trust, Canada; Canada Council, Canada; BCKDF, Canada; Hong Kong SAR, China; RGC, China; ISF, IsraelIsrael Science Foundation; Benoziyo Center, Israel; I-CORE, Israel; MEXT, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); INFN, ItalyIstituto Nazionale di Fisica Nucleare; NWO, NetherlandsNetherlands Organization for Scientific Research (NWO)Netherlands Government; FQRNT, CanadaFQRNT; MESTD, Serbia; Compute Canada, Canada; ERC, European UnionEuropean Union (EU)European Research Council (ERC); EPLANET, European UnionEuropean Union (EU); FP7, European UnionEuropean Union (EU); ERDF, European UnionEuropean Union (EU); Marie Sklodowska-Curie Actions, European UnionEuropean Union (EU); Horizon, European Union; MNiSW, PolandMinistry of Science and Higher Education, Poland; RCN, Norway; FCT, PortugalPortuguese Foundation for Science and Technology; NON, Poland; MES of Russia, Russian FederationRussian Federation; MNE/IFA, Romania; JINR; CRC, Canada; NRC KI, Russian Federation; CANARIE, Canada ; We acknowledge the support of ANPCyT, Argentina; YerPhI, Armenia; ARC, Australia; BMWFW and FWF, Austria; ANAS, Azerbaijan; SSTC, Belarus; CNPq and FAPESP, Brazil; NSERC, NRC and CFI, Canada; CERN; CONICYT, Chile; CAS, MOST and NSFC, China; COLCIENCIAS, Colombia; MSMT CR, MPO CR and VSC CR, Czech Republic; DNRF and DNSRC, Denmark; IN2P3-CNRS, CEA-DSM/IRFU, France; SRNSF, Georgia; BMBF, HGF, and MPG, Germany; GSRT, Greece; RGC, Hong Kong SAR, China; ISF, I-CORE and Benoziyo Center, Israel; INFN, Italy; MEXT and JSPS, Japan; CNRST, Morocco; NWO, Netherlands; RCN, Norway; MNiSW and NON, Poland; FCT, Portugal; MNE/IFA, Romania; MES of Russia and NRC KI, Russian Federation; JINR; MESTD, Serbia; MSSR, Slovakia; ARRS and MIZS, Slovenia; DST/NRF, South Africa; MINECO, Spain; SRC and Wallenberg Foundation, Sweden; SERI, SNSF and Cantons of Bern and Geneva, Switzerland; MOST, Taiwan; TAEK, Turkey; STFC, United Kingdom; DOE and NSF, United States of America. In addition, individual groups and members have received support from BCKDF, the Canada Council, CANARIE, CRC, Compute Canada, FQRNT, and the Ontario Innovation Trust, Canada; EPLANET, ERC, ERDF, FP7, Horizon 2020 and Marie Sklodowska-Curie Actions, European Union; Investissements d'Avenir Labex and Idex, ANR, Region Auvergne and Fondation Partager le Savoir, France; DFG and AvH Foundation, Germany; Herakleitos, Thales and Aristeia programmes co-financed by EU-ESF and the Greek NSRF; BSF, GIF and Minerva, Israel; BRF, Norway; CERCA Programme Generalitat de Catalunya, Generalitat Valenciana, Spain; the Royal Society and Leverhulme Trust, United Kingdom.
Publisher's version (útgefin grein) ; Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM−/− patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors. ; Peterlongo laboratory is supported by Associazione Italiana Ricerca sul Cancro (AIRC; IG2015 no.16732) to P. Peterlongo and by a fellowship from Fondazione Umberto Veronesi to G. Figlioli. Surrallés laboratory is supported by the ICREA-Academia program, the Spanish Ministry of Health (projects FANCOSTEM and FANCOLEN), the Spanish Ministry of Economy and Competiveness (projects CB06/07/0023 and RTI2018-098419-B-I00), the European Commission (EUROFANCOLEN project HEALTH-F5-2012-305421 and P-SPHERE COFUND project), the Fanconi Anemia Research Fund Inc, and the "Fondo Europeo de Desarrollo Regional, una manera de hacer Europa" (FEDER). CIBERER is an initiative of the Instituto de Salud Carlos III, Spain. BCAC: we thank all the individuals who took part in these studies and all the researchers, clinicians, technicians and administrative staff who have enabled this work to be carried out. ABCFS thank Maggie Angelakos, Judi Maskiell, Tu Nguyen-Dumont is a National Breast Cancer Foundation (Australia) Career Development Fellow. ABCS thanks the Blood bank Sanquin, The Netherlands. Samples are made available to researchers on a non-exclusive basis. BCEES thanks Allyson Thomson, Christobel Saunders, Terry Slevin, BreastScreen Western Australia, Elizabeth Wylie, Rachel Lloyd. The BCINIS study would not have been possible without the contributions of Dr. Hedy Rennert, Dr. K. Landsman, Dr. N. Gronich, Dr. A. Flugelman, Dr. W. Saliba, Dr. E. Liani, Dr. I. Cohen, Dr. S. Kalet, Dr. V. Friedman, Dr. O. Barnet of the NICCC in Haifa, and all the contributing family medicine, surgery, pathology and oncology teams in all medical institutes in Northern Israel. The BREOGAN study would not have been possible without the contributions of the following: Manuela Gago-Dominguez, Jose Esteban Castelao, Angel Carracedo, Victor Muñoz Garzón, Alejandro Novo Domínguez, Maria Elena Martinez, Sara Miranda Ponte, Carmen Redondo Marey, Maite Peña Fernández, Manuel Enguix Castelo, Maria Torres, Manuel Calaza (BREOGAN), José Antúnez, Máximo Fraga and the staff of the Department of Pathology and Biobank of the University Hospital Complex of Santiago-CHUS, Instituto de Investigación Sanitaria de Santiago, IDIS, Xerencia de Xestion Integrada de Santiago-SERGAS; Joaquín González-Carreró and the staff of the Department of Pathology and Biobank of University Hospital Complex of Vigo, Instituto de Investigacion Biomedica Galicia Sur, SERGAS, Vigo, Spain. BSUCH thanks Peter Bugert, Medical Faculty Mannheim. CBCS thanks study participants, co-investigators, collaborators and staff of the Canadian Breast Cancer Study, and project coordinators Agnes Lai and Celine Morissette. CCGP thanks Styliani Apostolaki, Anna Margiolaki, Georgios Nintos, Maria Perraki, Georgia Saloustrou, Georgia Sevastaki, Konstantinos Pompodakis. CGPS thanks staff and participants of the Copenhagen General Population Study. For the excellent technical assistance: Dorthe Uldall Andersen, Maria Birna Arnadottir, Anne Bank, Dorthe Kjeldgård Hansen. The Danish Cancer Biobank is acknowledged for providing infrastructure for the collection of blood samples for the cases. Investigators from the CPS-II cohort thank the participants and Study Management Group for their invaluable contributions to this research. They also acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention National Program of Cancer Registries, as well as cancer registries supported by the National Cancer Institute Surveillance Epidemiology and End Results program. The CTS Steering Committee includes Leslie Bernstein, Susan Neuhausen, James Lacey, Sophia Wang, Huiyan Ma, and Jessica Clague DeHart at the Beckman Research Institute of City of Hope, Dennis Deapen, Rich Pinder, and Eunjung Lee at the University of Southern California, Pam Horn-Ross, Peggy Reynolds, Christina Clarke Dur and David Nelson at the Cancer Prevention Institute of California, Hoda Anton-Culver, Argyrios Ziogas, and Hannah Park at the University of California Irvine, and Fred Schumacher at Case Western University. DIETCOMPLYF thanks the patients, nurses and clinical staff involved in the study. The DietCompLyf study was funded by the charity Against Breast Cancer (Registered Charity Number 1121258) and the NCRN. We thank the participants and the investigators of EPIC (European Prospective Investigation into Cancer and Nutrition). ESTHER thanks Hartwig Ziegler, Sonja Wolf, Volker Hermann, Christa Stegmaier, Katja Butterbach. FHRISK thanks NIHR for funding. GC-HBOC thanks Stefanie Engert, Heide Hellebrand, Sandra Kröber and LIFE - Leipzig Research Centre for Civilization Diseases (Markus Loeffler, Joachim Thiery, Matthias Nüchter, Ronny Baber). The GENICA Network: Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Germany [HB, Wing-Yee Lo], German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) [HB], Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy - EXC 2180 - 390900677 [HB], Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany [Yon-Dschun Ko, Christian Baisch], Institute of Pathology, University of Bonn, Germany [Hans-Peter Fischer], Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany [Ute Hamann], Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany [TB, Beate Pesch, Sylvia Rabstein, Anne Lotz]; and Institute of Occupational Medicine and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Germany [Volker Harth]. HABCS thanks Michael Bremer. HEBCS thanks Heidi Toiminen, Kristiina Aittomäki, Irja Erkkilä and Outi Malkavaara. HMBCS thanks Peter Hillemanns, Hans Christiansen and Johann H. Karstens. HUBCS thanks Shamil Gantsev. KARMA thanks the Swedish Medical Research Counsel. KBCP thanks Eija Myöhänen, Helena Kemiläinen. LMBC thanks Gilian Peuteman, Thomas Van Brussel, EvyVanderheyden and Kathleen Corthouts. MABCS thanks Milena Jakimovska (RCGEB "Georgi D. Efremov), Katerina Kubelka, Mitko Karadjozov (Adzibadem-Sistina" Hospital), Andrej Arsovski and Liljana Stojanovska (Re-Medika" Hospital) for their contributions and commitment to this study. MARIE thanks Petra Seibold, Dieter Flesch-Janys, Judith Heinz, Nadia Obi, Alina Vrieling, Sabine Behrens, Ursula Eilber, Muhabbet Celik, Til Olchers and Stefan Nickels. MBCSG (Milan Breast Cancer Study Group) thanks Daniela Zaffaroni, Irene Feroce, and the personnel of the Cogentech Cancer Genetic Test Laboratory. We thank the coordinators, the research staff and especially the MMHS participants for their continued collaboration on research studies in breast cancer. MSKCC thanks Marina Corines and Lauren Jacobs. MTLGEBCS would like to thank Martine Tranchant (CHU de Québec Research Center), Marie-France Valois, Annie Turgeon and Lea Heguy (McGill University Health Center, Royal Victoria Hospital; McGill University) for DNA extraction, sample management and skillful technical assistance. J.S. is Chairholder of the Canada Research Chair in Oncogenetics. NBHS thanks study participants and research staff for their contributions and commitment to the studies. We would like to thank the participants and staff of the Nurses' Health Study and Nurses' Health Study II for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The study protocol was approved by the institutional review boards of the Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health, and those of participating registries as required. The authors assume full responsibility for analyses and interpretation of these data. OFBCR thanks Teresa Selander and Nayana Weerasooriya. ORIGO thanks E. Krol-Warmerdam, and J. Blom for patient accrual, administering questionnaires, and managing clinical information. PBCS thanks Louise Brinton, Mark Sherman, Neonila Szeszenia-Dabrowska, Beata Peplonska, Witold Zatonski, Pei Chao and Michael Stagner. The ethical approval for the POSH study is MREC /00/6/69, UKCRN ID: 1137. We thank staff in the Experimental Cancer Medicine Centre (ECMC) supported Faculty of Medicine Tissue Bank and the Faculty of Medicine DNA Banking resource. PREFACE thanks Sonja Oeser and Silke Landrith. PROCAS thanks NIHR for funding. RBCS thanks Petra Bos, Jannet Blom, Ellen Crepin, Elisabeth Huijskens, Anja Kromwijk-Nieuwlaat, Annette Heemskerk, the Erasmus MC Family Cancer Clinic. We thank the SEARCH and EPIC teams. SKKDKFZS thanks all study participants, clinicians, family doctors, researchers and technicians for their contributions and commitment to this study. We thank the SUCCESS Study teams in Munich, Duessldorf, Erlangen and Ulm. SZBCS thanks Ewa Putresza. UCIBCS thanks Irene Masunaka. UKBGS thanks Breast Cancer Now and the Institute of Cancer Research for support and funding of the Breakthrough Generations Study, and the study participants, study staff, and the doctors, nurses and other health care providers and health information sources who have contributed to the study. We acknowledge NHS funding to the Royal Marsden/ICR NIHR Biomedical Research Centre. CIMBA: we are grateful to all the families and clinicians who contribute to the studies; Sue Healey, in particular taking on the task of mutation classification with the late Olga Sinilnikova; Maggie Angelakos, Judi Maskiell, Helen Tsimiklis; members and participants in the New York site of the Breast Cancer Family Registry; members and participants in the Ontario Familial Breast Cancer Registry; Vilius Rudaitis and Laimonas Griškevičius; Yuan Chun Ding and Linda Steele for their work in participant enrollment and biospecimen and data management; Bent Ejlertsen and Anne-Marie Gerdes for the recruitment and genetic counseling of participants; Alicia Barroso, Rosario Alonso and Guillermo Pita; all the individuals and the researchers who took part in CONSIT TEAM (Consorzio Italiano Tumori Ereditari Alla Mammella), thanks in particular: Giulia Cagnoli, Roberta Villa, Irene Feroce, Mariarosaria Calvello, Riccardo Dolcetti, Giuseppe Giannini, Laura Papi, Gabriele Lorenzo Capone, Liliana Varesco, Viviana Gismondi, Maria Grazia Tibiletti, Daniela Furlan, Antonella Savarese, Aline Martayan, Stefania Tommasi, Brunella Pilato, Isabella Marchi, Elena Bandieri, Antonio Russo, Daniele Calistri and the personnel of the Cogentech Cancer Genetic Test Laboratory, Milan, Italy. FPGMX: members of the Cancer Genetics group (IDIS): Ana Blanco, Miguel Aguado, Uxía Esperón and Belinda Rodríguez. We thank all participants, clinicians, family doctors, researchers, and technicians for their contributions and commitment to the DKFZ study and the collaborating groups in Lahore, Pakistan (Noor Muhammad, Sidra Gull, Seerat Bajwa, Faiz Ali Khan, Humaira Naeemi, Saima Faisal, Asif Loya, Mohammed Aasim Yusuf) and Bogota, Colombia (Diana Torres, Ignacio Briceno, Fabian Gil). Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO) study is a study from the National Cancer Genetics Network UNICANCER Genetic Group, France. We wish to pay a tribute to Olga M. Sinilnikova, who with Dominique Stoppa-Lyonnet initiated and coordinated GEMO until she sadly passed away on the 30th June 2014. The team in Lyon (Olga Sinilnikova, Mélanie Léoné, Laure Barjhoux, Carole Verny-Pierre, Sylvie Mazoyer, Francesca Damiola, Valérie Sornin) managed the GEMO samples until the biological resource centre was transferred to Paris in December 2015 (Noura Mebirouk, Fabienne Lesueur, Dominique Stoppa-Lyonnet). We want to thank all the GEMO collaborating groups for their contribution to this study. Drs.Sofia Khan, Irja Erkkilä and Virpi Palola; The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) consists of the following Collaborating Centers: Netherlands Cancer Institute (coordinating center), Amsterdam, NL: M.A. Rookus, F.B.L. Hogervorst, F.E. van Leeuwen, M.A. Adank, M.K. Schmidt, N.S. Russell, D.J. Jenner; Erasmus Medical Center, Rotterdam, NL: J.M. Collée, A.M.W. van den Ouweland, M.J. Hooning, C.M. Seynaeve, C.H.M. van Deurzen, I.M. Obdeijn; Leiden University Medical Center, NL: C.J. van Asperen, P. Devilee, T.C.T.E.F. van Cronenburg; Radboud University Nijmegen Medical Center, NL: C.M. Kets, A.R. Mensenkamp; University Medical Center Utrecht, NL: M.G.E.M. Ausems, M.J. Koudijs; Amsterdam Medical Center, NL: C.M. Aalfs, H.E.J. Meijers-Heijboer; VU University Medical Center, Amsterdam, NL: K. van Engelen, J.J.P. Gille; Maastricht University Medical Center, NL: E.B. Gómez-Garcia, M.J. Blok; University of Groningen, NL: J.C. Oosterwijk, A.H. van der Hout, M.J. Mourits, G.H. de Bock; The Netherlands Comprehensive Cancer Organisation (IKNL): S. Siesling, J.Verloop; The nationwide network and registry of histo- and cytopathology in The Netherlands (PALGA): A.W. van den Belt-Dusebout. HEBON thanks the study participants and the registration teams of IKNL and PALGA for part of the data collection. Overbeek; the Hungarian Breast and Ovarian Cancer Study Group members (Janos Papp, Aniko Bozsik, Zoltan Matrai, Miklos Kasler, Judit Franko, Maria Balogh, Gabriella Domokos, Judit Ferenczi, Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary) and the clinicians and patients for their contributions to this study; HVH (University Hospital Vall d'Hebron) the authors acknowledge the Oncogenetics Group (VHIO) and the High Risk and Cancer Prevention Unit of the University Hospital Vall d'Hebron, Miguel Servet Progam (CP10/00617), and the Cellex Foundation for providing research facilities and equipment; the ICO Hereditary Cancer Program team led by Dr. Gabriel Capella; the ICO Hereditary Cancer Program team led by Dr. Gabriel Capella; Dr Martine Dumont for sample management and skillful assistance; Catarina Santos and Pedro Pinto; members of the Center of Molecular Diagnosis, Oncogenetics Department and Molecular Oncology Research Center of Barretos Cancer Hospital; Heather Thorne, Eveline Niedermayr, all the kConFab investigators, research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (which has received funding from the NHMRC, the National Breast Cancer Foundation, Cancer Australia, and the National Institute of Health (USA)) for their contributions to this resource, and the many families who contribute to kConFab; the investigators of the Australia New Zealand NRG Oncology group; members and participants in the Ontario Cancer Genetics Network; Kevin Sweet, Caroline Craven, Julia Cooper, Amber Aielts, and Michelle O'Conor; Christina Selkirk; Helena Jernström, Karin Henriksson, Katja Harbst, Maria Soller, Ulf Kristoffersson; from Gothenburg Sahlgrenska University Hospital: Anna Öfverholm, Margareta Nordling, Per Karlsson, Zakaria Einbeigi; from Stockholm and Karolinska University Hospital: Anna von Wachenfeldt, Annelie Liljegren, Annika Lindblom, Brita Arver, Gisela Barbany Bustinza; from Umeå University Hospital: Beatrice Melin, Christina Edwinsdotter Ardnor, Monica Emanuelsson; from Uppsala University: Hans Ehrencrona, Maritta Hellström Pigg, Richard Rosenquist; from Linköping University Hospital: Marie Stenmark-Askmalm, Sigrun Liedgren; Cecilia Zvocec, Qun Niu; Joyce Seldon and Lorna Kwan; Dr. Robert Nussbaum, Beth Crawford, Kate Loranger, Julie Mak, Nicola Stewart, Robin Lee, Amie Blanco and Peggy Conrad and Salina Chan; Carole Pye, Patricia Harrington and Eva Wozniak. OSUCCG thanks Kevin Sweet, Caroline Craven, Julia Cooper, Michelle O'Conor and Amber Aeilts. BCAC is funded by Cancer Research UK [C1287/A16563, C1287/A10118], the European Union's Horizon 2020 Research and Innovation Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST respectively), and by the European Community´s Seventh Framework Programme under grant agreement number 223175 (grant number HEALTH-F2-2009-223175) (COGS). The EU Horizon 2020 Research and Innovation Programme funding source had no role in study design, data collection, data analysis, data interpretation or writing of the report. Genotyping of the OncoArray was funded by the NIH Grant U19 CA148065, and Cancer UK Grant C1287/A16563 and the PERSPECTIVE project supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research (grant GPH-129344) and, the Ministère de l'Économie, Science et Innovation du Québec through Genome Québec and the PSRSIIRI-701 grant, and the Quebec Breast Cancer Foundation. The Australian Breast Cancer Family Study (ABCFS) was supported by grant UM1 CA164920 from the National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. The ABCFS was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia) and the Victorian Breast Cancer Research Consortium. J.L.H. is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow. M.C.S. is a NHMRC Senior Research Fellow. The ABCS study was supported by the Dutch Cancer Society [grants NKI 2007-3839; 2009 4363]. The Australian Breast Cancer Tissue Bank (ABCTB) was supported by the National Health and Medical Research Council of Australia, The Cancer Institute NSW and the National Breast Cancer Foundation. The AHS study is supported by the intramural research program of the National Institutes of Health, the National Cancer Institute (grant number Z01-CP010119), and the National Institute of Environmental Health Sciences (grant number Z01-ES049030). The work of the BBCC was partly funded by ELAN-Fond of the University Hospital of Erlangen. The BBCS is funded by Cancer Research UK and Breast Cancer Now and acknowledges NHS funding to the NIHR Biomedical Research Centre, and the National Cancer Research Network (NCRN). The BCEES was funded by the National Health and Medical Research Council, Australia and the Cancer Council Western Australia. For the BCFR-NY, BCFR-PA, BCFR-UT this work was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR. BCINIS study was funded by the BCRF (The Breast Cancer Research Foundation, USA). The BREast Oncology GAlician Network (BREOGAN) is funded by Acción Estratégica de Salud del Instituto de Salud Carlos III FIS PI12/02125/Cofinanciado FEDER; Acción Estratégica de Salud del Instituto de Salud Carlos III FIS Intrasalud (PI13/01136); Programa Grupos Emergentes, Cancer Genetics Unit, Instituto de Investigacion Biomedica Galicia Sur. Xerencia de Xestion Integrada de Vigo-SERGAS, Instituto de Salud Carlos III, Spain; Grant 10CSA012E, Consellería de Industria Programa Sectorial de Investigación Aplicada, PEME I + D e I + D Suma del Plan Gallego de Investigación, Desarrollo e Innovación Tecnológica de la Consellería de Industria de la Xunta de Galicia, Spain; Grant EC11-192. Fomento de la Investigación Clínica Independiente, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain; and Grant FEDER-Innterconecta. Ministerio de Economia y Competitividad, Xunta de Galicia, Spain. The BSUCH study was supported by the Dietmar-Hopp Foundation, the Helmholtz Society and the German Cancer Research Center (DKFZ). Sample collection and processing was funded in part by grants from the National Cancer Institute (NCI R01CA120120 and K24CA169004). CBCS is funded by the Canadian Cancer Society (grant # 313404) and the Canadian Institutes of Health Research. CCGP is supported by funding from the University of Crete. The CECILE study was supported by Fondation de France, Institut National du Cancer (INCa), Ligue Nationale contre le Cancer, Agence Nationale de Sécurité Sanitaire, de l'Alimentation, de l'Environnement et du Travail (ANSES), Agence Nationale de la Recherche (ANR). The CGPS was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council, and Herlev and Gentofte Hospital. The American Cancer Society funds the creation, maintenance, and updating of the CPS-II cohort. The CTS was initially supported by the California Breast Cancer Act of 1993 and the California Breast Cancer Research Fund (contract 97-10500) and is currently funded through the National Institutes of Health (R01 CA77398, K05 CA136967, UM1 CA164917, and U01 CA199277). Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. The University of Westminster curates the DietCompLyf database funded by Against Breast Cancer Registered Charity No. 1121258 and the NCRN. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by: Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health Foundation, the Stavros Niarchos Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). The ESTHER study was supported by a grant from the Baden Württemberg Ministry of Science, Research and Arts. Additional cases were recruited in the context of the VERDI study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). FHRISK is funded from NIHR grant PGfAR 0707-10031. The GC-HBOC (German Consortium of Hereditary Breast and Ovarian Cancer) is supported by the German Cancer Aid (grant no 110837, coordinator: Rita K. Schmutzler, Cologne). This work was also funded by the European Regional Development Fund and Free State of Saxony, Germany (LIFE - Leipzig Research Centre for Civilization Diseases, project numbers 713-241202, 713-241202, 14505/2470, 14575/2470). The GENICA was funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, the Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. The GEPARSIXTO study was conducted by the German Breast Group GmbH. The GESBC was supported by the Deutsche Krebshilfe e. V. [70492] and the German Cancer Research Center (DKFZ). The HABCS study was supported by the Claudia von Schilling Foundation for Breast Cancer Research, by the Lower Saxonian Cancer Society, and by the Rudolf Bartling Foundation. The HEBCS was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society, and the Sigrid Juselius Foundation. The HMBCS was supported by a grant from the German Research Foundation (Do 761/10-1). The HUBCS was supported by a grant from the German Federal Ministry of Research and Education (RUS08/017), and by the Russian Foundation for Basic Research and the Federal Agency for Scientific Organizations for support the Bioresource collections and RFBR grants 14-04-97088, 17-29-06014 and 17-44-020498. E.K was supported by the program for support the bioresource collections №007-030164/2 and study was performed as part of the assignment of the Ministry of Science and Higher Education of Russian Federation (№АААА-А16-116020350032-1). Financial support for KARBAC was provided through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, the Swedish Cancer Society, The Gustav V Jubilee foundation and Bert von Kantzows foundation. The KARMA study was supported by Märit and Hans Rausings Initiative Against Breast Cancer. The KBCP was financially supported by the special Government Funding (EVO) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, and by the strategic funding of the University of Eastern Finland. LMBC is supported by the 'Stichting tegen Kanker'. DL is supported by the FWO. The MABCS study is funded by the Research Centre for Genetic Engineering and Biotechnology "Georgi D. Efremov" and supported by the German Academic Exchange Program, DAAD. The MARIE study was supported by the Deutsche Krebshilfe e.V. [70-2892-BR I, 106332, 108253, 108419, 110826, 110828], the Hamburg Cancer Society, the German Cancer Research Center (DKFZ) and the Federal Ministry of Education and Research (BMBF) Germany [01KH0402]. MBCSG is supported by grants from the Italian Association for Cancer Research (AIRC) and by funds from the Italian citizens who allocated the 5/1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects "5 × 1000"). The MCBCS was supported by the NIH grants CA192393, CA116167, CA176785 an NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201], and the Breast Cancer Research Foundation and a generous gift from the David F. and Margaret T. Grohne Family Foundation. MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057 and 396414, and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW), including the National Death Index and the Australian Cancer Database. The MEC was support by NIH grants CA63464, CA54281, CA098758, CA132839 and CA164973. The MISS study is supported by funding from ERC-2011-294576 Advanced grant, Swedish Cancer Society, Swedish Research Council, Local hospital funds, Berta Kamprad Foundation, Gunnar Nilsson. The MMHS study was supported by NIH grants CA97396, CA128931, CA116201, CA140286 and CA177150. MSKCC is supported by grants from the Breast Cancer Research Foundation and Robert and Kate Niehaus Clinical Cancer Genetics Initiative. The work of MTLGEBCS was supported by the Quebec Breast Cancer Foundation, the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program – grant # CRN-87521 and the Ministry of Economic Development, Innovation and Export Trade – grant # PSR-SIIRI-701. The NBHS was supported by NIH grant R01CA100374. Biological sample preparation was conducted the Survey and Biospecimen Shared Resource, which is supported by P30 CA68485. The Northern California Breast Cancer Family Registry (NC-BCFR) and Ontario Familial Breast Cancer Registry (OFBCR) were supported by grant UM1 CA164920 from the National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. The Carolina Breast Cancer Study was funded by Komen Foundation, the National Cancer Institute (P50 CA058223, U54 CA156733, U01 CA179715), and the North Carolina University Cancer Research Fund. The NHS was supported by NIH grants P01 CA87969, UM1 CA186107, and U19 CA148065. The NHS2 was supported by NIH grants UM1 CA176726 and U19 CA148065. The ORIGO study was supported by the Dutch Cancer Society (RUL 1997-1505) and the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL CP16). The PBCS was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. Genotyping for PLCO was supported by the Intramural Research Program of the National Institutes of Health, NCI, Division of Cancer Epidemiology and Genetics. The PLCO is supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health. The POSH study is funded by Cancer Research UK (grants C1275/A11699, C1275/C22524, C1275/A19187, C1275/A15956 and Breast Cancer Campaign 2010PR62, 2013PR044. PROCAS is funded from NIHR grant PGfAR 0707-10031. The RBCS was funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). SEARCH is funded by Cancer Research UK [C490/A10124, C490/A16561] and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. The University of Cambridge has received salary support for PDPP from the NHS in the East of England through the Clinical Academic Reserve. The Sister Study (SISTER) is supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01-ES044005 and Z01-ES049033). The Two Sister Study (2SISTER) was supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01-ES044005 and Z01-ES102245), and, also by a grant from Susan G. Komen for the Cure, grant FAS0703856. SKKDKFZS is supported by the DKFZ. The SMC is funded by the Swedish Cancer Foundation and the Swedish Research Council [grant 2017-00644 for the Swedish Infrastructure for Medical Population-based Life-course Environmental Research (SIMPLER)]. The SZBCS is financially supported under the program of Minister of Science and Higher Education "Regional Initiative of Excellence" in years 2019-2022, Grant No 002/RID/2018/19. The TNBCC was supported by: a Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a grant from the Breast Cancer Research Foundation, a generous gift from the David F. and Margaret T. Grohne Family Foundation. The UCIBCS component of this research was supported by the NIH [CA58860, CA92044] and the Lon V Smith Foundation [LVS39420]. The UKBGS is funded by Breast Cancer Now and the Institute of Cancer Research (ICR), London. ICR acknowledges NHS funding to the NIHR Biomedical Research Centre. The UKOPS study was funded by The Eve Appeal (The Oak Foundation) and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The USRT Study was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. CIMBA CIMBA: The CIMBA data management and data analysis were supported by Cancer Research – UK grants C12292/A20861, C12292/A11174. ACA is a Cancer Research -UK Senior Cancer Research Fellow. GCT and ABS are NHMRC Research Fellows. The PERSPECTIVE project was supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the Ministry of Economy, Science and Innovation through Genome Québec, and The Quebec Breast Cancer Foundation. BCFR: UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR. BFBOCC: Lithuania (BFBOCC-LT): Research Council of Lithuania grant SEN-18/2015 and Nr. P-MIP-19-164. BIDMC: Breast Cancer Research Foundation. BMBSA: Cancer Association of South Africa (PI Elizabeth J. van Rensburg). CNIO: Spanish Ministry of Health PI16/00440 supported by FEDER funds, the Spanish Ministry of Economy and Competitiveness (MINECO) SAF2014-57680-R and the Spanish Research Network on Rare diseases (CIBERER). COH-CCGCRN: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under grant number R25CA112486, and RC4CA153828 (PI: J. Weitzel) from the National Cancer Institute and the Office of the Director, National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. CONSIT TEAM: Associazione Italiana Ricerca sul Cancro (AIRC; IG2014 no.15547) to P. Radice. Funds from Italian citizens who allocated the 5 × 1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects '5 × 1000') to S. Manoukian. UNIROMA1: Italian Association for Cancer Research (AIRC; grant no. 21389) to L. Ottini. DFKZ: German Cancer Research Center. EMBRACE: Cancer Research UK Grants C1287/A10118 and C1287/A11990. D. Gareth Evans and Fiona Lalloo are supported by an NIHR grant to the Biomedical Research Centre, Manchester (IS-BRC-1215-20007). The Investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Ros Eeles and Elizabeth Bancroft are supported by Cancer Research UK Grant C5047/A8385. Ros Eeles is also supported by NIHR support to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. FCCC: NIH/NCI grant P30-CA006927. The University of Kansas Cancer Center (P30 CA168524) and the Kansas Bioscience Authority Eminent Scholar Program. A.K.G. was funded by R0 1CA140323, R01 CA214545, and by the Chancellors Distinguished Chair in Biomedical Sciences Professorship. Ana Vega is supported by the Spanish Health Research Foundation, Instituto de Salud Carlos III (ISCIII), partially supported by FEDER funds through Research Activity Intensification Program (contract grant numbers: INT15/00070, INT16/00154, INT17/00133), and through Centro de Investigación Biomédica en Red de Enferemdades Raras CIBERER (ACCI 2016: ER17P1AC7112/2018); Autonomous Government of Galicia (Consolidation and structuring program: IN607B), and by the Fundación Mutua Madrileña (call 2018). GC-HBOC: German Cancer Aid (grant no 110837, Rita K. Schmutzler) and the European Regional Development Fund and Free State of Saxony, Germany (LIFE - Leipzig Research Centre for Civilization Diseases, project numbers 713-241202, 713-241202, 14505/2470, 14575/2470). GEMO: Ligue Nationale Contre le Cancer; the Association "Le cancer du sein, parlons-en!" Award, the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program, the French National Institute of Cancer (INCa) (grants AOR 01 082, 2013-1-BCB-01-ICH-1 and SHS-E-SP 18-015) and the Fondation ARC pour la recherche sur le cancer (grant PJA 20151203365). GEORGETOWN: the Survey, Recruitment and Biospecimen Shared Resource at Georgetown University (NIH/NCI grant P30-CA051008) and the Fisher Center for Hereditary Cancer and Clinical Genomics Research. HCSC: Spanish Ministry of Health PI15/00059, PI16/01292, and CB-161200301 CIBERONC from ISCIII (Spain), partially supported by European Regional Development FEDER funds. HEBCS: Helsinki University Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society and the Sigrid Juselius Foundation. HEBON: the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756, the Netherlands Organization of Scientific Research grant NWO 91109024, the Pink Ribbon grants 110005 and 2014-187.WO76, the BBMRI grant NWO 184.021.007/CP46 and the Transcan grant JTC 2012 Cancer 12-054. HUNBOCS: Hungarian Research Grants KTIA-OTKA CK-80745 and NKFI_OTKA K-112228. HVH (University Hospital Vall d'Hebron) This work was supported by Spanish Instituto de Salud Carlos III (ISCIII) funding, an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds: FIS PI12/02585 and PI15/00355. ICO: The authors would like to particularly acknowledge the support of the Asociación Española Contra el Cáncer (AECC), the Instituto de Salud Carlos III (organismo adscrito al Ministerio de Economía y Competitividad) and "Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa" (PI10/01422, PI13/00285, PIE13/00022, PI15/00854, PI16/00563, P18/01029, and CIBERONC) and the Institut Català de la Salut and Autonomous Government of Catalonia (2009SGR290, 2014SGR338, 2017SGR449, and PERIS Project MedPerCan), and CERCA program. IHCC: PBZ_KBN_122/P05/2004. ILUH: Icelandic Association "Walking for Breast Cancer Research" and by the Landspitali University Hospital Research Fund. INHERIT: Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program – grant # CRN-87521 and the Ministry of Economic Development, Innovation and Export Trade – grant # PSR-SIIRI-701. IOVHBOCS: Ministero della Salute and "5 × 1000" Istituto Oncologico Veneto grant. IPOBCS: Liga Portuguesa Contra o Cancro. kConFab: The National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. MAYO: NIH grants CA116167, CA192393 and CA176785, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), and a grant from the Breast Cancer Research Foundation. MCGILL: Jewish General Hospital Weekend to End Breast Cancer, Quebec Ministry of Economic Development, Innovation and Export Trade. Marc Tischkowitz is supported by the funded by the European Union Seventh Framework Program (2007Y2013)/European Research Council (Grant No. 310018). MSKCC: the Breast Cancer Research Foundation, the Robert and Kate Niehaus Clinical Cancer Genetics Initiative, the Andrew Sabin Research Fund and a Cancer Center Support Grant/Core Grant (P30 CA008748). NCI: the Intramural Research Program of the US National Cancer Institute, NIH, and by support services contracts NO2-CP-11019-50, N02-CP-21013-63 and N02-CP-65504 with Westat, Inc, Rockville, MD. NNPIO: the Russian Foundation for Basic Research (grants 17-54-12007, 17-00-00171 and 18-515-45012). NRG Oncology: U10 CA180868, NRG SDMC grant U10 CA180822, NRG Administrative Office and the NRG Tissue Bank (CA 27469), the NRG Statistical and Data Center (CA 37517) and the Intramural Research Program, NCI. OSUCCG: was funded by the Ohio State University Comprehensive Cancer Center. PBCS: Italian Association of Cancer Research (AIRC) [IG 2013 N.14477] and Tuscany Institute for Tumors (ITT) grant 2014-2015-2016. SMC: the Israeli Cancer Association. SWE-BRCA: the Swedish Cancer Society. UCHICAGO: NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA125183), R01 CA142996, 1U01CA161032 and by the Ralph and Marion Falk Medical Research Trust, the Entertainment Industry Fund National Women's Cancer Research Alliance and the Breast Cancer research Foundation. UCSF: UCSF Cancer Risk Program and Helen Diller Family Comprehensive Cancer Center. UKFOCR: Cancer Researc h UK. UPENN: National Institutes of Health (NIH) (R01-CA102776 and R01-CA083855; Breast Cancer Research Foundation; Susan G. Komen Foundation for the cure, Basser Research Center for BRCA. UPITT/MWH: Hackers for Hope Pittsburgh. VFCTG: Victorian Cancer Agency, Cancer Australia, National Breast Cancer Foundation. WCP: Dr Karlan is funded by the American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the National Center for Advancing Translational Sciences (NCATS), Grant UL1TR000124. ; Peer Reviewed
BMWFW (Austria) ; FWF (Austria) ; FNRS (Belgium) ; FWO (Belgium) ; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) ; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) ; Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) ; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) ; MES (Bulgaria) ; CERN ; CAS (China) ; MoST (China) ; NSFC (China) ; COLCIENCIAS (Colombia) ; MSES (Croatia) ; CSF (Croatia) ; RPF (Cyprus) ; MoER (Estonia) ; ERC IUT (Estonia) ; ERDF (Estonia) ; Academy of Finland (Finland) ; MEC (Finland) ; HIP (Finland) ; CEA (France) ; CNRS/IN2P3 (France) ; BMBF (Germany) ; DFG (Germany) ; HGF (Germany) ; GSRT (Greece) ; OTKA (Hungary) ; NIH (Hungary) ; DAE (India) ; DST (India) ; IPM (Iran) ; SFI (Ireland) ; INFN (Italy) ; MSIP (Republic of Korea) ; NRF (Republic of Korea) ; LAS (Lithuania) ; MOE (Malaysia) ; UM (Malaysia) ; CINVESTAV (Mexico) ; CONACYT (Mexico) ; SEP (Mexico) ; UASLP-FAI (Mexico) ; MBIE (NewZealand) ; PAEC (Pakistan) ; MSHE (Poland) ; NSC (Poland) ; FCT (Portugal) ; JINR (Dubna) ; MON (Russia) ; RosAtom (Russia) ; RAS (Russia) ; RFBR (Russia) ; MESTD (Serbia) ; SEIDI (Spain) ; CPAN (Spain) ; Swiss Funding Agencies (Switzerland) ; MST (Taipei) ; ThEPCenter (Thailand) ; IPST (Thailand) ; STAR (Thailand) ; NSTDA (Thailand) ; TUBITAK (Turkey) ; TAEK (Turkey) ; NASU (Ukraine) ; SFFR (Ukraine) ; STFC (United Kingdom) ; DOE (USA) ; NSF (USA) ; Marie-Curie programme ; European Research Council ; EPLANET (European Union) ; Leventis Foundation ; A. P. Sloan Foundation ; Alexander von Humboldt Foundation ; Belgian Federal Science Policy Office ; Fonds pour la Formation a la Recherche dans l'Industrie et dans l'Agriculture (FRIA-Belgium) ; Agentschap voor Innovatie door Wetenschap en Technologie (IWT-Belgium) ; Ministry of Education, Youth and Sports (MEYS) of the Czech Republic ; Council of Science and Industrial Research, India ; HOMING PLUS programme of the Foundation for Polish Science ; European Union, Regional Development Fund ; Mobility Plus programme of the Ministry of Science and Higher Education (Poland) ; OPUS programme of the National Science Center (Poland) ; MIUR (Italy) ; Thalis programme - EU-ESF ; Aristeia programme - EU-ESF ; Greek NSRF ; National Priorities Research Program by Qatar National Research Fund ; Rachadapisek Sompot Fund for Postdoctoral Fellowship, Chulalongkorn University (Thailand) ; Chulalongkorn Academic into Its 2nd Century Project Advancement Project (Thailand) ; Welch Foundation ; Science and Technology Facilities Council ; MIUR (Italy): 20108T4XTM ; Welch Foundation: C-1845 ; Science and Technology Facilities Council: ST/J004871/1 ; Science and Technology Facilities Council: ST/I003622/1 ; Science and Technology Facilities Council: ST/M004775/1 GRIDPP ; Science and Technology Facilities Council: ST/K003542/1 GRID PP ; Science and Technology Facilities Council: ST/M004775/1 ; Science and Technology Facilities Council: PP/E000479/1 ; Science and Technology Facilities Council: ST/N000250/1 ; Science and Technology Facilities Council: PP/E002803/1 ; Science and Technology Facilities Council: CMS ; Science and Technology Facilities Council: GRIDPP ; Science and Technology Facilities Council: ST/H000925/1 ; Science and Technology Facilities Council: ST/N000242/1 ; Science and Technology Facilities Council: ST/K003542/1 ; Science and Technology Facilities Council: ST/J005479/1 ; Science and Technology Facilities Council: ST/H000925/2 ; Science and Technology Facilities Council: ST/K001531/1 ; Science and Technology Facilities Council: ST/I000305/1 ; Science and Technology Facilities Council: ST/K003542/1 GRIDPP ; Science and Technology Facilities Council: ST/I003622/1 GRIDPP ; Science and Technology Facilities Council: ST/K001639/1 ; Science and Technology Facilities Council: ST/L005603/1 ; Science and Technology Facilities Council: ST/K003224/1 CMS Upgrades ; Science and Technology Facilities Council: ST/K001256/1 ; Science and Technology Facilities Council: ST/N001273/1 ; Science and Technology Facilities Council: ST/K001639/1 CMS Upgrades ; Science and Technology Facilities Council: ST/M002020/1 ; A search for narrow resonances decaying to an electron and a muon is presented. The e mu mass spectrum is also investigated for non-resonant contributions from the production of quantum black holes (QBHs). The analysis is performed using data corresponding to an integrated luminosity of 19.7 fb(-1) collected in proton-proton collisions at a centre-of-mass energy of 8 TeV with the CMS detector at the LHC. With no evidence for physics beyond the standard model in the invariant mass spectrum of selected e mu pairs, upper limits are set at 95 % confidence level on the product of cross section and branching fraction for signals arising in theories with charged lepton flavour violation. In the search for narrow resonances, the resonant production of a tau sneutrino in R-parity violating supersymmetry is considered. The t sneutrino is excluded for masses below 1.28 TeV for couplings lambda(132) = lambda(231) = lambda(')(311) = 0.01, and below 2.30 TeV for lambda(132) = lambda(231) = 0.07 and lambda(')(311) = 0.11. These are the most stringent limits to date from direct searches at high-energy colliders. In addition, the resonance searches are interpreted in terms of a model with heavy partners of the Z boson and the photon. In a framework of TeV-scale quantum gravity based on a renormalization of Newton's constant, the search for non-resonant contributions to the e mu mass spectrum excludes QBH production below a threshold mass M-th of 1.99 TeV. In models that invoke extra dimensions, the bounds range from 2.36 TeV for one extra dimension to 3.63 TeV for six extra dimensions. This is the first search for QBHs decaying into the e mu final state.
BMWFW (Austria) ; FWF (Austria) ; FNRS (Belgium) ; FWO (Belgium) ; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) ; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) ; Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) ; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) ; MES (Bulgaria) ; CERN ; CAS (China) ; MoST (China) ; NSFC (China) ; COLCIENCIAS (Colombia) ; MSES (Croatia) ; CSF (Croatia) ; RPF (Cyprus) ; MoER (Estonia) ; ERC IUT (Estonia) ; ERDF (Estonia) ; Academy of Finland (Finland) ; MEC (Finland) ; HIP (Finland) ; CEA (France) ; CNRS/IN2P3 (France) ; BMBF (Germany) ; DFG (Germany) ; HGF (Germany) ; GSRT (Greece) ; OTKA (Hungary) ; NIH (Hungary) ; DAE (India) ; DST (India) ; IPM (Iran) ; SFI (Ireland) ; INFN (Italy) ; MSIP (Republic of Korea) ; NRF (Republic of Korea) ; LAS (Lithuania) ; MOE (Malaysia) ; UM (Malaysia) ; CINVESTAV (Mexico) ; CONACYT (Mexico) ; SEP (Mexico) ; UASLP-FAI (Mexico) ; MBIE (New Zealand) ; PAEC (Pakistan) ; MSHE (Poland) ; NSC (Poland) ; FCT (Portugal) ; JINR (Dubna) ; MON (Russia) ; RosAtom (Russia) ; RAS (Russia) ; RFBR (Russia) ; MESTD (Serbia) ; SEIDI (Spain) ; CPAN (Spain) ; Swiss Funding Agencies (Switzerland) ; MST (Taipei) ; ThEPCenter (Thailand) ; IPST (Thailand) ; STAR (Thailand) ; NSTDA (Thailand) ; TUBITAK (Turkey) ; TAEK (Turkey) ; NASU (Ukraine) ; SFFR (Ukraine) ; STFC (United Kingdom) ; DOE (USA) ; NSF (USA) ; Marie-Curie programme (European Union) ; European Research Council (European Union) ; EPLANET (European Union) ; Leventis Foundation ; A. P. Sloan Foundation ; Alexander von Humboldt Foundation ; Belgian Federal Science Policy Office ; Fonds pour la Formation a la Recherche dans l'Industrie et dans l'Agriculture (FRIA-Belgium) ; Agentschap voor Innovatie door Wetenschap en Technologie (IWT-Belgium) ; Ministry of Education, Youth and Sports (MEYS) of the Czech Republic ; Council of Science and Industrial Research, India ; HOMING PLUS programme of the Foundation for Polish Science - European Union, Regional Development Fund ; OPUS programme of the National Science Center (Poland) ; Compagnia di San Paolo (Torino) ; MIUR (Italy) ; Thalis programme - EU-ESF ; Aristeia programme - EU-ESF ; Greek NSRF ; National Priorities Research Program by Qatar National Research Fund ; Chulalongkorn University (Thailand) ; Chulalongkorn Academic into Its 2nd Century Project Advancement Project (Thailand) ; Welch Foundation ; Science and Technology Facilities Council ; MIUR (Italy): 20108T4XTM ; Welch Foundation: C-1845 ; Science and Technology Facilities Council: PP/E002803/1 ; Science and Technology Facilities Council: ST/K003542/1 GRIDPP ; Science and Technology Facilities Council: ST/K003224/1 CMS Upgrades ; Science and Technology Facilities Council: ST/M002020/1 ; Science and Technology Facilities Council: ST/K003542/1 ; Science and Technology Facilities Council: ST/L00609X/1 GRIDPP ; Science and Technology Facilities Council: ST/K001639/1 CMS Upgrades ; Science and Technology Facilities Council: ST/M004775/1 ; Science and Technology Facilities Council: ST/J005665/1 ; Science and Technology Facilities Council: ST/N000250/1 ; Science and Technology Facilities Council: ST/M004775/1 GRIDPP ; Science and Technology Facilities Council: ST/L005603/1 ; Science and Technology Facilities Council: ST/J004871/1 ; Science and Technology Facilities Council: GRIDPP ; Science and Technology Facilities Council: ST/J004901/1 ; Science and Technology Facilities Council: ST/H000925/1 ; Science and Technology Facilities Council: ST/J005479/1 ; Science and Technology Facilities Council: ST/K003542/1 GRID PP ; Science and Technology Facilities Council: PP/E000479/1 ; Science and Technology Facilities Council: ST/L00609X/1 ; Science and Technology Facilities Council: ST/I003622/1 ; Science and Technology Facilities Council: ST/K001639/1 ; Science and Technology Facilities Council: ST/K003844/1 GRIDPP ; Science and Technology Facilities Council: ST/N000242/1 ; Science and Technology Facilities Council: ST/N001273/1 ; Science and Technology Facilities Council: ST/H000925/2 ; Science and Technology Facilities Council: ST/M005356/1 ; Science and Technology Facilities Council: ST/M005356/1 GRIDPP ; Science and Technology Facilities Council: ST/I005912/1 ; Science and Technology Facilities Council: ST/I003622/1 GRIDPP ; Science and Technology Facilities Council: ST/I005912/1 GRIDPP ; Science and Technology Facilities Council: ST/K003844/1 ; Science and Technology Facilities Council: ST/K001256/1 ; Science and Technology Facilities Council: ST/I000305/1 ; Science and Technology Facilities Council: CMS ; Science and Technology Facilities Council: ST/K001531/1 ; A search for a massive resonance W'decaying into a W and a Higgs boson in the l nu b (b) over bar (l = e, mu) final state is presented. Results are based on data corresponding to an integrated luminosity of 19.7 fb(-1) of proton-proton collisions at root s = 8 TeV, collected using the CMS detector at the LHC. For a high-mass (greater than or similar to 1 TeV) resonance, the two bottom quarks coming from the Higgs boson decay are reconstructed as a single jet, which can be tagged by placing requirements on its substructure and flavour. Exclusion limits at 95 % confidence level are set on the production cross section of a narrow resonance decaying into WH, as a function of its mass. In the context of a little Higgs model, a lower limit on the W' mass of 1.4 TeV is set. In a heavy vector triplet model that mimics the properties of composite Higgs models, a lower limit on the W' mass of 1.5 TeV is set. In the context of this model, the results are combined with related searches to obtain a lower limit on the W' mass of 1.8 TeV, the most restrictive to date for decays to a pair of standard model bosons.
BMWFW (Austria) ; FWF (Austria) ; FNRS (Belgium) ; FWO (Belgium) ; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) ; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) ; Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) ; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) ; MES (Bulgaria) ; CERN ; CAS (China) ; MOST (China) ; NSFC (China) ; COLCIENCIAS (Colombia) ; MSES (Croatia) ; CSF (Croatia) ; RPF (Cyprus) ; MoER (Estonia) ; ERC IUT (Estonia) ; ERDF (Estonia) ; Academy of Finland (Finland) ; MEC (Finland) ; HIP (Finland) ; CEA (France) ; CNRS/IN2P3 (France) ; BMBF (Germany) ; DFG (Germany) ; HGF (Germany) ; GSRT (Greece) ; OTKA (Hungary) ; NIH (Hungary) ; DAE (India) ; DST (India) ; IPM (Iran) ; SFI (Ireland) ; INFN (Italy) ; MSIP (Republic of Korea) ; NRF (Republic of Korea) ; LAS (Lithuania) ; MOE (Malaysia) ; UM (Malaysia) ; CINVESTAV (Mexico) ; CONACYT (Mexico) ; SEP (Mexico) ; UASLP-FAI (Mexico) ; MBIE (New Zealand) ; PAEC (Pakistan) ; MSHE (Poland) ; NSC (Poland) ; FCT (Portugal) ; JINR (Dubna) ; MON (Russia) ; RosAtom (Russia) ; RAS (Russia) ; RFBR (Russia) ; MESTD (Serbia) ; SEIDI (Spain) ; CPAN (Spain) ; Swiss Funding Agencies (Switzerland) ; MST (Taipei) ; ThEPCenter (Thailand) ; IPST (Thailand) ; STAR (Thailand) ; NSTDA (Thailand) ; TUBITAK (Turkey) ; TAEK (Turkey) ; NASU (Ukraine) ; SFFR (Ukraine) ; STFC (United Kingdom) ; DOE (USA) ; NSF (USA) ; Marie-Curie program ; European Research Council ; EPLANET (European Union) ; Leventis Foundation ; A.P. Sloan Foundation ; Alexander von Humboldt Foundation ; Belgian Federal Science Policy Office ; Fonds pour la Formation a la Recherche dans l'Industrie et dans l'Agriculture ( FRIA- Belgium) ; Agentschap voor Innovatie door Wetenschap en Technologie (IWT-Belgium) ; Ministry of Education, Youth and Sports (MEYS) of the Czech Republic ; Council of Science and Industrial Research, India ; HOMING PLUS program of the Foundation for Polish Science ; European Union, Regional Development Fund ; OPUS program of the National Science Center (Poland) ; Compagnia di San Paolo (Torino) ; MIUR (Italy) ; Thalis and Aristeia programs - EU-ESF and the Greek NSRF ; National Priorities Research Program by Qatar National Research Fund ; Rachadapisek Sompot Fund for Postdoctoral Fellowship ; Chulalongkorn University (Thailand) ; Chulalongkorn Academic into Its 2nd Century Project Advancement Project (Thailand) ; Welch Foundation ; Science and Technology Facilities Council ; MIUR (Italy): 20108T4XTM ; Welch Foundation: C-1845 ; Science and Technology Facilities Council: ST/J005479/1 ; Science and Technology Facilities Council: ST/L00609X/1 ; Science and Technology Facilities Council: ST/K003542/1 GRID PP ; Science and Technology Facilities Council: ST/N001273/1 ; Science and Technology Facilities Council: ST/M004775/1 ; Science and Technology Facilities Council: ST/N000242/1 ; Science and Technology Facilities Council: ST/K003844/1 GRIDPP ; Science and Technology Facilities Council: ST/K003844/1 ; Science and Technology Facilities Council: ST/I005912/1 GRIDPP ; Science and Technology Facilities Council: ST/K001639/1 ; Science and Technology Facilities Council: ST/I005912/1 ; Science and Technology Facilities Council: ST/H000925/2 ; Science and Technology Facilities Council: ST/J005665/1 ; Science and Technology Facilities Council: ST/M004775/1 GRIDPP ; Science and Technology Facilities Council: ST/K003542/1 GRIDPP ; Science and Technology Facilities Council: ST/K001256/1 ; Science and Technology Facilities Council: CMS ; Science and Technology Facilities Council: ST/H000925/1 ; Science and Technology Facilities Council: ST/L00609X/1 GRIDPP ; Science and Technology Facilities Council: PP/E000479/1 ; Science and Technology Facilities Council: ST/J004901/1 ; Science and Technology Facilities Council: ST/L005603/1 ; Science and Technology Facilities Council: ST/K001639/1 CMS Upgrades ; Science and Technology Facilities Council: ST/K001531/1 ; Science and Technology Facilities Council: ST/K003542/1 ; Science and Technology Facilities Council: ST/N000250/1 ; Science and Technology Facilities Council: ST/I003622/1 ; Science and Technology Facilities Council: PP/E002803/1 ; Science and Technology Facilities Council: ST/J004871/1 ; Science and Technology Facilities Council: ST/I003622/1 GRIDPP ; Science and Technology Facilities Council: ST/M002020/1 ; Science and Technology Facilities Council: GRIDPP ; Science and Technology Facilities Council: ST/I000305/1 ; Science and Technology Facilities Council: ST/M005356/1 GRIDPP ; Science and Technology Facilities Council: ST/M005356/1 ; Science and Technology Facilities Council: ST/K003224/1 CMS Upgrades ; The results of a search for a supersymmetric partner of the top quark (top squark), pair-produced in proton-proton collisions at root s = 8 TeV, are presented. The search, which focuses on R-parity violating, chargino-mediated decays of the top squark, is performed in final states with low missing transverse momentum, two oppositely charged electrons or muons, and at least five jets. The analysis uses a data sample corresponding to an integrated luminosity of 19.7 fb(-1)collected with the CMS detector at the LHC in 2012. The data are found to be in agreement with the standard model expectation, and upper limits are placed on the top squark pair production cross section at 95% confidence level. Assuming a 100% branching fraction for the top squark decay chain, (t) over tilde -> t (chi) over tilde (+/-)(1), (chi) over tilde (+/-)(1) -> l(+/-) + jj, top squark masses less than 890(1000) GeV for the electron (muon) channel are excluded for the first time in models with a single nonzero R-parity violating coupling. lambda'(ijk) (i, j, k <= 2), where i, j, k correspond to the three generations. (C) 2016 The Author(s). Published by Elsevier B.V.
BMWFW (Austria) ; FWF (Austria) ; FNRS (Belgium) ; FWO (Belgium) ; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) ; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) ; Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) ; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) ; MES (Bulgaria) ; CERN ; CAS (China) ; MoST (China) ; NSFC (China) ; COLCIENCIAS (Colombia) ; MSES (Croatia) ; CSF (Croatia) ; RPF (Cyprus) ; MoER (Estonia) ; ERC IUT (Estonia) ; ERDF (Estonia) ; Academy of Finland (Finland) ; MEC (Finland) ; HIP (Finland) ; CEA (France) ; CNRS/IN2P3 (France) ; BMBF (Germany) ; DFG (Germany) ; HGF (Germany) ; GSRT (Greece) ; OTKA (Hungary) ; NIH (Hungary) ; DAE (India) ; DST (India) ; IPM (Iran) ; SFI (Ireland) ; INFN (Italy) ; MSIP (Republic of Korea) ; NRF (Republic of Korea) ; LAS (Lithuania) ; MOE (Malaysia) ; UM (Malaysia) ; CINVESTAV (Mexico) ; CONACYT (Mexico) ; SEP (Mexico) ; UASLP-FAI (Mexico) ; MBIE (New Zealand) ; PAEC (Pakistan) ; MSHE (Poland) ; NSC (Poland) ; FCT (Portugal) ; JINR (Dubna) ; MON (Russia) ; RosAtom (Russia) ; RAS (Russia) ; RFBR (Russia) ; MESTD (Serbia) ; SEIDI (Spain) ; CPAN (Spain) ; Swiss Funding Agencies (Switzerland) ; MST (Taipei) ; ThEPCenter (Thailand) ; IPST (Thailand) ; STAR (Thailand) ; NSTDA (Thailand) ; TUBITAK (Turkey) ; TAEK (Turkey) ; NASU (Ukraine) ; SFFR (Ukraine) ; STFC (United Kingdom) ; DOE (U.S.A.) ; NSF (U.S.A.) ; Marie-Curie program ; European Research Council ; EPLANET (European Union) ; Leventis Foundation ; A. P. Sloan Foundation ; Alexander von Humboldt Foundation ; Belgian Federal Science Policy Office ; Fonds pour la Formation a la Recherche dans l'Industrie et dans l'Agriculture (FRIA-Belgium) ; Agentschap voor Innovatie door Wetenschap en Technologie (IWT-Belgium) ; Ministry of Education, Youth and Sports (MEYS) of the Czech Republic ; Council of Science and Industrial Research, India ; HOMING PLUS program of the Foundation for Polish Science ; European Union, Regional Development Fund ; OPUS program of the National Science Center (Poland) ; Compagnia di San Paolo (Torino) ; MIUR (Italy) ; Thalis program - EU-ESF ; Aristeia program - EU-ESF ; Greek NSRF ; National Priorities Research Program by Qatar National Research Fund ; Rachadapisek Sompot Fund for Postdoctoral Fellowship, Chulalongkorn University (Thailand) ; Chulalongkorn Academic into Its 2nd Century Project Advancement Project (Thailand) ; Welch Foundation ; Science and Technology Facilities Council ; MIUR (Italy): 20108T4XTM ; Welch Foundation: C-1845 ; Science and Technology Facilities Council: ST/K003542/1 GRIDPP ; Science and Technology Facilities Council: ST/M002020/1 ; Science and Technology Facilities Council: ST/N001273/1 ; Science and Technology Facilities Council: ST/N000242/1 ; Science and Technology Facilities Council: ST/I005912/1 ; Science and Technology Facilities Council: ST/I000305/1 ; Science and Technology Facilities Council: ST/N000250/1 ; Science and Technology Facilities Council: ST/J50094X/1 ; Science and Technology Facilities Council: ST/L005603/1 ; Science and Technology Facilities Council: ST/M004775/1 GRIDPP ; Science and Technology Facilities Council: GRIDPP ; Science and Technology Facilities Council: ST/K001256/1 ; Science and Technology Facilities Council: PP/E002803/1 ; Science and Technology Facilities Council: ST/H000925/2 ; Science and Technology Facilities Council: ST/J005479/1 ; Science and Technology Facilities Council: ST/H000925/1 ; Science and Technology Facilities Council: ST/I003622/1 ; Science and Technology Facilities Council: ST/J004871/1 ; Science and Technology Facilities Council: ST/K003844/1 ; Science and Technology Facilities Council: ST/M005356/1 GRIDPP ; Science and Technology Facilities Council: CMS ; Science and Technology Facilities Council: PP/E000479/1 ; Science and Technology Facilities Council: ST/I005912/1 GRIDPP ; Science and Technology Facilities Council: ST/M005356/1 ; Science and Technology Facilities Council: ST/I003622/1 GRIDPP ; Science and Technology Facilities Council: ST/J005665/1 ; Science and Technology Facilities Council: ST/L00609X/1 ; Science and Technology Facilities Council: ST/K003542/1 ; Science and Technology Facilities Council: ST/K003542/1 GRID PP ; Science and Technology Facilities Council: ST/L00609X/1 GRIDPP ; Science and Technology Facilities Council: ST/K001639/1 CMS Upgrades ; Science and Technology Facilities Council: ST/M004775/1 ; Science and Technology Facilities Council: ST/J004901/1 ; Science and Technology Facilities Council: ST/K001639/1 ; Science and Technology Facilities Council: ST/K003224/1 CMS Upgrades ; Science and Technology Facilities Council: ST/K001531/1 ; Science and Technology Facilities Council: ST/K003844/1 GRIDPP ; The quark-gluon plasma is studied via medium-induced changes to correlations between jets and charged particles in PbPb collisions compared to pp reference data. This analysis uses data sets from PbPb and pp collisions with integrated luminosities of 166 mu b(-1) and 5.3 pb(-1), respectively, collected at root s(NN) = 2.76 TeV. The angular distributions of charged particles are studied as a function of relative pseudorapidity (Delta eta) and relative azimuthal angle (Delta phi) with respect to reconstructed jet directions. Charged particles are correlated with all jets with transverse momentum (p(T)) above 120 GeV, and with the leading and subleading jets (the highest and second-highest in p(T), respectively) in a selection of back-to-back dijet events. Modifications in PbPb data relative to pp reference data are characterized as a function of PbPb collision centrality and charged particle p(T). A centrality-dependent excess of low-p(T) particles is present for all jets studied, and is most pronounced in the most central events. This excess of low-p(T) particles follows a Gaussian-like distribution around the jet axis, and extends to large relative angles of Delta eta approximate to 1 and Delta phi approximate to 1.
BMWFW (Austria) ; FWF (Austria) ; FNRS (Belgium) ; FWO (Belgium) ; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) ; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) ; Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) ; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) ; MES (Bulgaria) ; CERN ; CAS (China) ; MOST (China) ; NSFC (China) ; COLCIENCIAS (Colombia) ; MSES (Croatia) ; CSF (Croatia) ; RPF (Cyprus) ; MoER (Estonia) ; ERC IUT (Estonia) ; ERDF (Estonia) ; Academy of Finland (Finland) ; MEC (Finland) ; HIP (Finland) ; CEA (France) ; CNRS/IN2P3 (France) ; BMBF (Germany) ; DFG (Germany) ; HGF (Germany) ; GSRT (Greece) ; OTKA (Hungary) ; NIH (Hungary) ; DAE (India) ; DST (India) ; IPM (Iran) ; SFI (Ireland) ; INFN (Italy) ; MSIP (Republic of Korea) ; NRF (Republic of Korea) ; LAS (Lithuania) ; MOE (Malaysia) ; UM (Malaysia) ; CINVESTAV (Mexico) ; CONACYT (Mexico) ; SEP (Mexico) ; UASLP-FAI (Mexico) ; MBIE (New Zealand) ; PAEC (Pakistan) ; MSHE (Poland) ; FCT (Portugal) ; JINR (Dubna) ; MON (Russia) ; RosAtom (Russia) ; RAS (Russia) ; RFBR (Russia) ; MESTD (Serbia) ; ThEPCenter (Thailand) ; IPST (Thailand) ; STAR (Thailand) ; NSTDA (Thailand) ; TUBITAK (Turkey) ; TAEK (Turkey) ; NASU (Ukraine) ; SFFR (Ukraine) ; STFC (United Kingdom) ; DOE (USA) ; NSF (USA) ; Marie-Curie programme (European Union) ; European Research Council (European Union) ; Leventis Foundation ; Alfred P. Sloan Foundation ; Alexander von Humboldt Foundation ; Belgian Federal Science Policy Office ; Fonds pour la Formation a la Recherche dans l'Industrie et dans l'Agriculture (FRIA-Belgium) ; Agentschap voor Innovatie door Wetenschap en Technologie (IWT-Belgium) ; Ministry of Education, Youth and Sports (MEYS) of the Czech Republic ; Council of Science and Industrial Research, India ; HOMING PLUS programme of the Foundation for Polish Science ; European Union, Regional Development Fund ; OPUS programme of the National Science Center (Poland) ; Compagnia di San Paolo (Torino) ; MIUR project (Italy) ; Thalis programme - EU-ESF ; Aristeia programme - EU-ESF ; Greek NSRF ; National Priorities Research Program by Qatar National Research Fund ; Rachadapisek Sompot Fund for Postdoctoral Fellowship, Chulalongkorn University (Thailand) ; Chulalongkorn Academic into Its 2nd Century Project Advancement Project (Thailand) ; Welch Foundation ; EPLANET (European Union) ; Science and Technology Facilities Council ; MIUR project (Italy): 20108T4XTM ; Welch Foundation: C-1845 ; Science and Technology Facilities Council: ST/N000250/1 ; Science and Technology Facilities Council: ST/L005603/1 ; Science and Technology Facilities Council: ST/H000925/2 ; Science and Technology Facilities Council: ST/M002020/1 ; Science and Technology Facilities Council: ST/K003542/1 ; Science and Technology Facilities Council: ST/K001639/1 ; Science and Technology Facilities Council: ST/I003622/1 ; Science and Technology Facilities Council: ST/K001256/1 ; Science and Technology Facilities Council: ST/M004775/1 ; Science and Technology Facilities Council: PP/E000479/1 ; Science and Technology Facilities Council: ST/K003224/1 CMS Upgrades ; Science and Technology Facilities Council: ST/I003622/1 GRIDPP ; Science and Technology Facilities Council: ST/H000925/1 ; Science and Technology Facilities Council: ST/N000242/1 ; Science and Technology Facilities Council: ST/J004871/1 ; Science and Technology Facilities Council: ST/M004775/1 GRIDPP ; Science and Technology Facilities Council: ST/K003542/1 GRID PP ; Science and Technology Facilities Council: ST/N001273/1 ; Science and Technology Facilities Council: ST/I000305/1 ; Science and Technology Facilities Council: ST/J005479/1 ; Science and Technology Facilities Council: ST/K001531/1 ; Science and Technology Facilities Council: PP/E002803/1 ; Science and Technology Facilities Council: ST/K001639/1 CMS Upgrades ; Science and Technology Facilities Council: GRIDPP ; Science and Technology Facilities Council: CMS ; Science and Technology Facilities Council: ST/K003542/1 GRIDPP ; Results are presented from a search for super symmetric particles in scenarios with small mass splittings. The data sample corresponds to 19.7 fb(-1) of proton-proton collisions recorded by the CMS experiment at root s = 8 TeV. The search targets top squark ((t) over tilde) pair production in scenarios with mass differences Delta m = m((t) over tilde) - m((chi) over tilde (0)(1)) below the W-boson mass and with top-squark decays in the four-body mode ((t) over tilde -> bl nu(chi) over tilde (0)(1)), where the neutralino ((chi) over tilde (0)(1)) is assumed to be the lightest supersymmetric particle (LSP). The signature includes a high transverse momentum (p(T)) jet associated with initial-state radiation, one or two low-p(T) leptons, and significant missing transverse energy. The event yields observed in data are consistent with the expected background contributions from standard model processes. Limits are set on the cross section for top squark pair production as a function of the (t) over tilde t and LSP masses. Assuming a 100% branching fraction for the four-body decay mode, top-squark masses below 316 GeV are excluded for Delta m = 25 GeV at 95% CL. The dilepton data are also interpreted under the assumption of chargino-neutralino production, with subsequent decays to sleptons or sneutrinos. Assuming a difference between the common ($) over tilde (+)(1)/(chi) over tilde (0)(2) mass and the LSP mass of 20 GeV and a tau-enriched decay scenario, masses in the range m((chi) over tilde (+)(1)) < 307 GeV are excluded at 95% CL. (C) 2016 The Author. Published by Elsevier B.V.
BMWFW (Austria) ; FWF (Austria) ; FNRS (Belgium) ; FWO (Belgium) ; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) ; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) ; Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) ; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) ; MES (Bulgaria) ; CERN ; CAS (China) ; MoST (China) ; NSFC (China) ; COLCIENCIAS (Colombia) ; MSES (Croatia) ; CSF (Croatia) ; RPF (Cyprus) ; MoER (Estonia) ; ERC IUT (Estonia) ; ERDF (Estonia) ; Academy of Finland (Finland) ; MEC (Finland) ; HIP (Finland) ; CEA (France) ; CNRS/IN2P3 (France) ; BMBF (Germany) ; DFG (Germany) ; HGF (Germany) ; GSRT (Greece) ; OTKA (Hungary) ; NIH (Hungary) ; DAE (India) ; DST (India) ; IPM (Iran) ; SFI (Ireland) ; INFN (Italy) ; MSIP (Republic of Korea) ; NRF (Republic of Korea) ; LAS (Lithuania) ; MOE (Malaysia) ; UM (Malaysia) ; CINVESTAV (Mexico) ; CONACYT (Mexico) ; SEP (Mexico) ; UASLP-FAI (Mexico) ; MBIE (New Zealand) ; PAEC (Pakistan) ; MSHE (Poland) ; NSC (Poland) ; FCT (Portugal) ; JINR (Dubna) ; MON (Russia) ; RosAtom (Russia) ; RAS (Russia) ; RFBR (Russia) ; MESTD (Serbia) ; SEIDI (Spain) ; CPAN (Spain) ; Swiss Funding Agencies (Switzerland) ; MST (Taipei) ; ThEPCenter (Thailand) ; IPST (Thailand) ; STAR (Thailand) ; NSTDA (Thailand) ; TUBITAK (Turkey) ; TAEK (Turkey) ; NASU (Ukraine) ; SFFR (Ukraine) ; STFC (United Kingdom) ; DOE (USA) ; NSF (USA) ; Marie-Curie programme (European Union) ; European Research Council (European Union) ; EPLANET (European Union) ; Leventis Foundation ; Alfred P. Sloan Foundation ; Alexander von Humboldt Foundation ; Belgian Federal Science Policy Office ; Fonds pour la Formation a la Recherche dans l'Industrie et dans l'Agriculture (FRIA-Belgium) ; Agentschap voor Innovatie door Wetenschap en Technologie (IWT-Belgium) ; Ministry of Education, Youth and Sports (MEYS) of the Czech Republic ; Council of Science and Industrial Research, India ; HOMING PLUS programme of the Foundation for Polish Science ; European Union ; Regional Development Fund ; OPUS programme of the National Science Centre (Poland) ; Compagnia di San Paolo (Torino) ; MIUR project (Italy) ; Thalis programme - EU-ESF ; Aristeia programme - EU-ESF ; Greek NSRF ; National Priorities Research Program by Qatar National Research Fund ; Rachadapisek Sompot Fund for Postdoctoral Fellowship, Chulalongkorn University (Thailand) ; Chulalongkorn Academic into Its 2nd Century Project Advancement Project (Thailand) ; Welch Foundation ; Science and Technology Facilities Council ; MIUR project (Italy): 20108T4XTM ; Welch Foundation: C-1845 ; Science and Technology Facilities Council: ST/I003622/1 ; Science and Technology Facilities Council: ST/K003844/1 GRIDPP ; Science and Technology Facilities Council: ST/M004775/1 ; Science and Technology Facilities Council: ST/N000242/1 ; Science and Technology Facilities Council: ST/K001639/1 ; Science and Technology Facilities Council: ST/N000250/1 ; Science and Technology Facilities Council: ST/K001256/1 ; Science and Technology Facilities Council: CMS ; Science and Technology Facilities Council: ST/L00609X/1 ; Science and Technology Facilities Council: ST/H000925/2 ; Science and Technology Facilities Council: ST/J005479/1 ; Science and Technology Facilities Council: ST/K003542/1 GRID PP ; Science and Technology Facilities Council: ST/L00609X/1 GRIDPP ; Science and Technology Facilities Council: ST/I000305/1 ; Science and Technology Facilities Council: GRIDPP ; Science and Technology Facilities Council: ST/J005665/1 ; Science and Technology Facilities Council: ST/K001639/1 CMS Upgrades ; Science and Technology Facilities Council: ST/K003542/1 ; Science and Technology Facilities Council: ST/K001531/1 ; Science and Technology Facilities Council: ST/K003224/1 CMS Upgrades ; Science and Technology Facilities Council: ST/M004775/1 GRIDPP ; Science and Technology Facilities Council: ST/J004901/1 ; Science and Technology Facilities Council: ST/I005912/1 ; Science and Technology Facilities Council: ST/L005603/1 ; Science and Technology Facilities Council: PP/E002803/1 ; Science and Technology Facilities Council: ST/M002020/1 ; Science and Technology Facilities Council: ST/K003844/1 ; Science and Technology Facilities Council: ST/J004871/1 ; Science and Technology Facilities Council: ST/I005912/1 GRIDPP ; Science and Technology Facilities Council: ST/I003622/1 GRIDPP ; Science and Technology Facilities Council: ST/H000925/1 ; Science and Technology Facilities Council: ST/N001273/1 ; Science and Technology Facilities Council: PP/E000479/1 ; Science and Technology Facilities Council: ST/M005356/1 GRIDPP ; Science and Technology Facilities Council: ST/K003542/1 GRIDPP ; Science and Technology Facilities Council: ST/M005356/1 ; A search for anomalous pseudoscalar couplings of the Higgs boson H to electroweak vector bosons V (= W or Z) in a sample of proton-proton collision events corresponding to an integrated luminosity of 18.9 fb(-1) at a center-of-mass energy of 8 TeV is presented. Events consistent with the topology of associated VH production, where the Higgs boson decays to a pair of bottom quarks and the vector boson decays leptonically, are analyzed. The consistency of data with a potential pseudoscalar contribution to the HVV interaction, expressed by the effective pseudoscalar cross section fractions f(a3), is assessed by means of profile likelihood scans. Results are given for the VH channels alone and for a combined analysis of the VH and previously published H -> VV channels. Under certain assumptions, f(a3)(ZZ) > 0.0034 is excluded at 95% confidence level in the combination. Scenarios in which these assumptions are relaxed are also considered. (C) 2016 The Author. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
ENIGMA-CNV working group. ; Low-frequency 1q21.1 distal deletion and duplication copy number variant (CNV) carriers are predisposed to multiple neurodevelopmental disorders, including schizophrenia, autism and intellectual disability. Human carriers display a high prevalence of micro- and macrocephaly in deletion and duplication carriers, respectively. The underlying brain structural diversity remains largely unknown. We systematically called CNVs in 38 cohorts from the large-scale ENIGMA-CNV collaboration and the UK Biobank and identified 28 1q21.1 distal deletion and 22 duplication carriers and 37,088 non-carriers (48% male) derived from 15 distinct magnetic resonance imaging scanner sites. With standardized methods, we compared subcortical and cortical brain measures (all) and cognitive performance (UK Biobank only) between carrier groups also testing for mediation of brain structure on cognition. We identified positive dosage effects of copy number on intracranial volume (ICV) and total cortical surface area, with the largest effects in frontal and cingulate cortices, and negative dosage effects on caudate and hippocampal volumes. The carriers displayed distinct cognitive deficit profiles in cognitive tasks from the UK Biobank with intermediate decreases in duplication carriers and somewhat larger in deletion carriers—the latter potentially mediated by ICV or cortical surface area. These results shed light on pathobiological mechanisms of neurodevelopmental disorders, by demonstrating gene dose effect on specific brain structures and effect on cognitive function. ; 1000BRAINS: The 1000BRAINS study was funded by the Institute of Neuroscience and Medicine, Research Center Juelich, Germany. We thank the Heinz Nixdorf Foundation (Germany) for the generous support of the Heinz Nixdorf Recall Study on which 1000BRAINS is based. We also thank the scientists and the study staff of the Heinz Nixdorf Recall Study and 1000BRAINS. Funding was also granted by the Initiative and Networking Fund of the Helmholtz Association (Caspers) and the European Union's Horizon 2020 Research and Innovation Programme under Grant Agreement 945539 (Human Brain Project SGA3; Amunts, Caspers, Cichon). Brainscale: The Brainscale study was supported by the Netherlands Organization for Scientific Research MagW 480-04-004 (Dorret I. Boomsma), 51.02.060 (Hilleke E. Hulshoff Pol), 668.772 (Dorret I. Boomsma and Hilleke E. Hulshoff Pol); NWO/SPI 56-464-14192 (Dorret I. Boomsma), the European Research Council (ERC-230374) (Dorret I. Boomsma), High Potential Grant Utrecht University (Hilleke E.Hulshoff Pol) and NWO Brain and Cognition 433-09-220 (Hilleke E.Hulshoff Pol). Betula: The Betula study was funded by the Knut and Alice Wallenberg (KAW) foundation (Nyberg). The Freesurfer segmentations on the Betula sample were performed on resources provided by the Swedish National Infrastructure for Computing (SNIC) at HPC2N (in Umeå, Sweden), partially funded by the Swedish Research Council through grant agreement no. 2018-05973. Brain Imaging Genetics (BIG): This work makes use of the BIG database, first established in Nijmegen, The Netherlands, in 2007. This resource is now part of Cognomics (www.cognomics.nl), a joint initiative by researchers from the Donders Centre for Cognitive Neuroimaging, the Human Genetics and Cognitive Neuroscience departments of the Radboud University Medical Centre and the Max Planck Institute for Psycholinguistics in Nijmegen. The Cognomics Initiative has received support from the participating departments and centres and from external grants, that is, the Biobanking and Biomolecular Resources Research Infrastructure (Netherlands) (BBMRI-NL), the Hersenstichting Nederland and the Netherlands Organization for Scientific Research (NWO). The research leading to these results also receives funding from the NWO Gravitation grant 'Language in Interaction', the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement nos. 602450 (IMAGEMEND), 278948 (TACTICS) and 602805 (Aggressotype), as well as from the European Community's Horizon 2020 programme under grant agreement no. 643051 (MiND) and from ERC-2010-AdG 268800-NEUROSCHEMA. In addition, the work was supported by a grant for the ENIGMA Consortium (grant number U54 EB020403) from the BD2K Initiative of a cross-NIH partnership. deCODE genetics: deCODE genetics acknowledges support from the Innovative Medicines Initiative Joint Undertaking under grant agreement nos. 115008 (NEWMEDS) and 115300 (EUAIMS), of which resources are composed of EFPIA in-kind contribution and financial contribution from the European Union's Seventh Framework Programme (EU-FP7/2007-2013), EU-FP7-funded grant agreement no. 602450 (IMAGEMEND) and EU-funded FP7-People-2011-IAPP grant agreement no. 286213 (PsychDPC). Dublin: This work was supported by Science Foundation Ireland (SFI grant 12/IP/1359 to Gary Donohoe and grant SFI08/IN.1/B1916-Corvin to Aidan C. Corvin). ECHO-DEFINE: The ECHO study acknowledges funding from a Medical Research Council (MRC) Centre Grant to Michael J. Owen (G0801418), the Wellcome Trust (Institutional Strategic Support Fund (ISSF) to van den Bree and Clinical Research Training Fellowship to Joanne L. Doherty), the Waterloo Foundation (WF 918-1234 to van den Bree), the Baily Thomas Charitable Fund (2315/1 to van den Bree), National Institute of Mental Health (NIMH 5UO1MH101724 to van den Bree and Michael J. Owen), the IMAGINE-2 study (funded by the MRC (MR/T033045/1) to van den Bree, Jeremy Hall and Michael J. Owen), the IMAGINE-ID study (funded by MRC (MR/N022572/1) to Jeremy Hall, van den Bree and Owen). The DEFINE study was supported by a Wellcome Trust Strategic Award (100202/Z/12/Z) to Michael J. Owen. ENIGMA: ENIGMA is supported in part by NIH grants U54 EB20403, R01MH116147 and R56AG058854. NIA T32AG058507; NIH/NIMH 5T32MH073526. EPIGEN-Dublin: The EPIGEN-Dublin cohort was supported by a Science Foundation Ireland Research Frontiers Programme award (08/RFP/GEN1538). EPIGEN-UK (Sisodiya): The work was partly undertaken at UCLH/UCL, which received a proportion of funding from the UK Department of Health's NIHR Biomedical Research Centres funding scheme. We are grateful to the Wolfson Trust and the Epilepsy Society for supporting the Epilepsy Society MRI scanner. GAP: This work was supported by the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, Psychology and Neuroscience, King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. GOBS: The GOBS study data collection was supported in part by the National Institutes of Health (NIH) grants: R01 MH078143, R01 MH078111 and R01 MH083824, with work conducted in part in facilities constructed under the support of NIH grant C06 RR020547. GSP: Data were in part provided by the Brain Genomics Superstruct Project (GSP) of Harvard University and Massachusetts General Hospital (MGH) (Principal Investigators: Randy Buckner, Jordan Smoller and Joshua Roffman), with support from the Center for Brain Science Neuroinformatics Research Group, Athinoula A. Martinos Center for Biomedical Imaging, Center for Genomic Medicine and Stanley Center for Psychiatric Research. Twenty individual investigators at Harvard and MGH generously contributed data to the overall project. We would like to thank Randy Buckner for insightful comments and feedback on this work. HUBIN: The HUBIN study was financed by the Swedish Research Council (K2010-62X-15078-07-2, K2012-61X-15078-09-3, 521-2014-3487 K2015-62X-15077-12-3, 2017-00949), the regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet. HUNT: The HUNT study is a collaboration between HUNT Research Centre (Faculty of Medicine and Movement Sciences, NTNU—Norwegian University of Science and Technology), Nord-Trøndelag County Council, Central Norway Health Authority and the Norwegian Institute of Public Health. HUNT-MRI was funded by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology, and the Norwegian National Advisory Unit for functional MRI. IMAGEN: This work received support from the following sources: the European Union-funded FP6 Integrated Project IMAGEN (reinforcement-related behaviour in normal brain function and psychopathology) (LSHM-CT- 2007-037286), the Horizon 2020 funded ERC Advanced Grant 'STRATIFY' (Brain network based stratification of reinforcement-related disorders) (695313), ERANID (Understanding the Interplay between Cultural, Biological and Subjective Factors in Drug Use Pathways) (PR-ST-0416-10004), BRIDGET (JPND: BRain Imaging, cognition Dementia and next generation GEnomics) (MR/N027558/1), Human Brain Project (HBP SGA 2, 785907),the FP7 projects IMAGEMEND(602450; IMAging GEnetics for MENtal Disorders) and MATRICS (603016), the Innovative Medicine Initiative Project EUAIMS (115300-2), the Medical Research Council Grant 'c-VEDA' (Consortium on Vulnerability to Externalizing Disorders and Addictions) (MR/N000390/1), the Swedish Research Council FORMAS, the Medical Research Council, the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, the Bundesministeriumfür Bildung und Forschung (BMBF grants 01GS08152, 01EV0711; eMED SysAlc01ZX1311A; Forschungsnetz AERIAL 01EE1406A, 01EE1406B), the Deutsche Forschungsgemeinschaft (DFG grants, SM 80/7-2, SFB 940/2), the Medical Research Foundation and Medical Research Council (grants MR/R00465X/1 and MR/S020306/1). Further support was provided by grants from: ANR (project AF12-NEUR0008-01—WM2NA, ANR-12-SAMA-0004), the Eranet Neuron (ANR-18-NEUR00002-01), the Fondation de France (00081242), the Fondation pour la Recherche Médicale (DPA20140629802), the Mission Interministérielle de Lutte-contre-les-Drogues-et-les-Conduites-Addictives (MILDECA), the Assistance-Publique-Hôpitaux-de-Paris and INSERM (interface grant), Paris Sud University IDEX 2012, the Fondation de l'Avenir (grant AP-RM-17-013), the Fédération pour la Recherche sur le Cerveau; the National Institutes of Health, Science Foundation Ireland (16/ERCD/3797), USA (Axon, Testosterone and Mental Health during Adolescence; RO1 MH085772-01A1) and by NIH Consortium grant U54 EB020403, supported by a cross-NIH alliance that funds Big Data to Knowledge Centres of Excellence. Lifespan: The study is funded by the Research Council of Norway (230345, 288083 and 223273). NCNG: NCNG sample collection was supported by grants from the Bergen Research Foundation and the University of Bergen, the Dr Einar Martens Fund, the Research Council of Norway, to le Hellard, Steen and Espeseth. The Bergen group was supported by grants from the Western Norway Regional Health Authority (Grant 911593 to Arvid Lundervold, Grant 911397 and 911687 to Astri Johansen Lundervold). NTR: The NTR cohort was supported by the Netherlands Organization for Scientific Research (NWO) and The Netherlands Organisation for Health Research and Development (ZonMW) grants 904-61-090, 985-10-002, 912-10-020, 904-61-193, 480-04-004,463-06-001, 451-04-034, 400-05-717, Addiction-31160008, 016-115-035, 481-08-011, 056-32-010, Middelgroot-911-09-032, OCW_NWO Gravity programme—024.001.003, NWO-Groot 480-15-001/674, Center for Medical Systems Biology (CSMB, NWO Genomics), NBIC/BioAssist/RK(2008.024), Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL, 184.021.007 and 184.033.111); Spinozapremie (NWO-56-464-14192), KNAW Academy Professor Award (PAH/6635) and University Research Fellow grant (URF) to Dorret I. Boomsma; Amsterdam Public Health research institute (former EMGO+), Neuroscience Amsterdam research institute (former NCA); the European Science Foundation (ESF, EU/QLRT-2001-01254), the European Community's Seventh Framework Programme (FP7- HEALTH-F4-2007-2013, grant 01413: ENGAGE and grant 602768: ACTION); the European Research Council (ERC Starting 284167, ERC Consolidator 771057, ERC Advanced 230374), Rutgers University Cell and DNA Repository (NIMH U24 MH068457-06), the National Institutes of Health (NIH, R01D0042157-01A1, R01MH58799-03, MH081802, DA018673, R01 DK092127-04, Grand Opportunity grants 1RC2 MH089951 and 1RC2 MH089995); the Avera Institute for Human Genetics, Sioux Falls, South Dakota (USA). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health. Computing was supported by NWO through grant 2018/EW/00408559, BiG Grid, the Dutch e-Science Grid and SURFSARA. OATS: The OATS study has been funded by a National Health & Medical Research Council (NHMRC) and Australian Research Council (ARC) Strategic Award Grant of the Ageing Well, Ageing Productively Programme (ID No. 401162) and NHMRC Project Grants (ID Nos. 1045325 and 1085606). This research was facilitated through Twins Research Australia, a national resource in part supported by an NHMRC Centre for Research Excellence Grant (ID No.: 1079102). We thank the participants for their time and generosity in contributing to this research. We acknowledge the contribution of the OATS research team (https://cheba.unsw.edu.au/project/older-australian-twins-study) to this study. OATS genotyping was partly funded by a Commonwealth Scientific and Industrial Research Organization Flagship Collaboration Fund Grant. Osaka: Osaka study was supported by the Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS: Grant Number JP18dm0207006), Brain/MINDS& beyond studies (Grant Number JP20dm0307002) and Health and Labour Sciences Research Grants for Comprehensive Research on Persons with Disabilities (Grant Number JP20dk0307081) from the Japan Agency for Medical Research and Development (AMED), Grants-in-Aid for Scientific Research (KAKENHI; Grant Numbers JP25293250 and JP16H05375). Some computations were performed at the Research Center for Computational Science, Okazaki, Japan. PAFIP: The PAFIP study was supported by Instituto de Salud Carlos III, FIS 00/3095, 01/3129, PI020499, PI060507, PI10/00183, the SENY Fundació Research Grant CI2005-0308007 and the FundaciónMarqués de Valdecilla API07/011. Biological samples from our cohort were stored at the Valdecilla Biobank and genotyping services were conducted at the Spanish 'Centro Nacional de Genotipado' (CEGEN-ISCIII). MCIC/COBRE: The study is funded by the National Institutes of Health studies R01EB006841, P20GM103472 and P30GM122734 and Department of Energy DE-FG02-99ER62764. PING: Data collection and sharing for the Paediatric Imaging, Neurocognition and Genetics (PING) Study (National Institutes of Health Grant RC2DA029475) were funded by the National Institute on Drug Abuse and the Eunice Kennedy Shriver National Institute of Child Health & Human Development. A full list of PING investigators is at http://pingstudy.ucsd.edu/investigators.html. QTIM: The QTIM study was supported by the National Institute of Child Health and Human Development (R01 HD050735) and the National Health and Medical Research Council (NHMRC 486682, 1009064), Australia. Genotyping was supported by NHMRC (389875). Medland is supported in part by an NHMRC fellowship (APP1103623). SHIP: SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grant nos. 01ZZ9603, 01ZZ0103 and 01ZZ0403), the Ministry of Cultural Affairs and the Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide single-nucleotide polymorphism typing in SHIP and MRI scans in SHIP and SHIP-TREND have been supported by a joint grant from Siemens Healthineers, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania. StrokeMRI: StrokeMRI was supported by the Norwegian ExtraFoundation for Health and Rehabilitation(2015/FO5146), the Research Council of Norway (249795, 262372), the South-Eastern Norway Regional Health Authority (2014097, 2015044, 2015073) and the Department of Psychology, University of Oslo. Sydney MAS: The Sydney Memory and Aging Study (Sydney MAS) is funded by National and HealthMedical Research Council (NHMRC) Programme and Project Grants (ID350833, ID568969 and ID109308). We also thank the Sydney MAS participants and the Research Team. SYS: The SYS Study is supported by Canadian Institutes of Health Research. TOP: Centre of Excellence: RCN #23273 and RCN #226971. Part of this work was performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo, operated and developed by the TSD service group at the University of Oslo, IT-Department (USIT) (tsd-drift@usit.uio.no). The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7-PEOPLE-2013-COFUND) under grant agreement no. 609020—Scientia Fellows; the Research Council of Norway (RCN) #276082—A lifespan perspective on mental illness: toward precision medicine using multimodal brain imaging and genetics. Ida E. Sønderby and Rune Bøen are supported by South-Eastern Norway Regional Health Authority (#2020060). Ida E. Sønderby and Ole A. Andreassen have received funding from the European Union's Horizon 2020 Research and Innovation Programme under Grant agreement no. 847776 (CoMorMent project) and the KG Jebsen Foundation (SKGJ-MED-021). UCLA_UMCU: The UCLA_UMCU cohort comprises of six studies which were supported by National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD) (20244 to Prof. Hillegers), The Netherlands Organisation for Health Research and Development (ZonMw) (908-02-123 to Prof. Hulshoff Pol), and Netherlands Organisation for Scientific Research (NWO 9120818 and NWO-VIDI 917-46-370 to Prof. Hulshoff Pol). The GROUP study was funded through the Geestkracht programme of the Dutch Health Research Council (ZonMw, grant number 10-000-1001), and matching funds from participating pharmaceutical companies (Lundbeck, AstraZeneca, Eli Lilly and Janssen Cilag) and universities and mental health care organizations (Amsterdam: Academic Psychiatric Centre of the Academic Medical Center and the mental health institutions: GGZ inGeest, Arkin, Dijk en Duin, GGZ Rivierduinen, Erasmus Medical Centre, GGZ Noord-Holland-Noord. Groningen: University Medical Center Groningen and the mental health institutions: Lentis, GGZ Friesland, GGZ Drenthe, Dimence, Mediant, GGNet Warnsveld, Yulius Dordrecht and Parnassia Psycho-medical Center, The Hague. Maastricht: Maastricht University Medical Centre and the mental health institutions: GGzE, GGZ Breburg, GGZ Oost-Brabant, Vincent van Gogh, voor Geestelijke Gezondheid, Mondriaan, Virenzeriagg, Zuyderland GGZ, MET ggz, Universitair Centrum Sint-JozefKortenberg, CAPRI University of Antwerp, PC Ziekeren Sint-Truiden, PZ Sancta Maria Sint-Truiden, GGZ Overpelt, OPZ Rekem. Utrecht: University Medical Center Utrecht and the mental health institutions: Altrecht, GGZ Centraal and Delta.). UK Biobank: This work made use of data sharing from UK Biobank (under project code 27412). Others: Work by Pierre Vanderhaeghen was funded by Grants of the European Research Council (ERC Adv Grant GENDEVOCORTEX), the EOS Programme, the Belgian FWO, the AXA Research Fund and the Belgian Queen Elizabeth Foundation. Ikuo K. Suzuki was supported by a postdoctoral fellowship of the FRS/FNRS. ; Peer reviewed